



Published in final edited form as:

Mech Ageing Dev. 2020 September ; 190: 111297. doi:10.1016/j.mad.2020.111297.

Compounds that extend longevity are protective in neurodegenerative diseases and provide a novel treatment strategy for these devastating disorders

Sonja K. Soo^{1,2,*}, Paige D. Rudich^{1,2,*}, Annika Traa^{1,2,*}, Namasth e Harris-Gauthier^{1,2,*}, Hazel J. Shields^{1,2,*}, Jeremy M. Van Raamsdonk^{1,2,3,4}

¹Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, H4A 3J1, Canada

²Metabolic Disorders and Complications Program, and Brain Repair and Integrative Neuroscience Program, Research Institute of the McGill University Health Centre, Montreal, Quebec, H4A 3J1, Canada

³Division of Experimental Medicine, Department of Medicine, McGill University, Montreal, Quebec, H4A 3J1, Canada

⁴Department of Genetics, Harvard Medical School, Boston MA 02115, USA

Abstract


While aging is the greatest risk factor for the development of neurodegenerative disease, the role of aging in these diseases is poorly understood. In the inherited forms of these diseases, the disease-causing mutation is present from birth but symptoms appear decades later. This indicates that these mutations are well tolerated in younger individuals but not in older adults. Based on this observation, we hypothesized that changes taking place during normal aging make the cells in the brain (and elsewhere) susceptible to the disease-causing mutations. If so, then delaying some of these age-related changes may be beneficial in the treatment of neurodegenerative disease. In this review, we examine the effects of five compounds that have been shown to extend longevity (metformin, rapamycin, resveratrol, N-acetyl-L-cysteine, curcumin) in four of the most common neurodegenerative diseases (Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis). While not all investigations observe a beneficial effect of these compounds, there are multiple studies that show a protective effect of each of these lifespan-extending compounds in animal models of neurodegenerative disease. Combined with genetic studies, this suggests the possibility that targeting the aging process may be an effective strategy to treat neurodegenerative disease.

Corresponding author: Jeremy M. Van Raamsdonk, Department of Neurology and Neurosurgery, McGill University, MeDiC and BRaIN Programs, McGill University Health Centre, 1001 Decarie Boulevard, Montreal, Quebec, H4A 3J1, 514-934-1934 ext. 76157, jeremy.vanraamsdonk@mcgill.ca.

*These authors contributed equally to this work

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Graphical Abstract



Keywords

Aging; Alzheimer's disease; Parkinson's disease; Huntington's disease; amyotrophic lateral sclerosis

1. Introduction

Neurodegenerative diseases are characterized by the progressive dysfunction and degeneration of neurons in the brain and peripheral nervous system. These devastating disorders affect more than 50 million people worldwide. Although genetic and environmental risk factors have been identified for all of these diseases, the pathogenesis of these diseases remains incompletely understood. While symptomatic treatments are available for some of these disorders, there are currently no disease-modifying treatments that can slow disease progression or halt the loss of neurons. As aging is the greatest risk factor for many of these adult-onset neurodegenerative diseases, including Alzheimer's and Parkinson's disease, it will be important to determine if interventions that extend lifespan can protect against these devastating disorders.

1.1 Alzheimer's disease (AD).

AD is the most common neurodegenerative disorder. AD and other dementias affect 40 to 50 million people worldwide (Nichols et al., 2019). While there are rare cases of early-onset familial AD affecting individuals under 65 years of age, AD typically affects individuals over 65 years of age, and over 95% of AD cases are sporadic cases. Moreover, the risk of AD doubles every 5 years after the age of 65. AD is characterized by difficulties with memory, language, problem-solving and cognitive functions. Brains of AD patients are marked by amyloid plaques, which contain amyloid beta ($A\beta$), and neurofibrillary tangles, which contain hyperphosphorylated tau. Degeneration starts in the medial temporal lobe, spreads to the hippocampus and amygdala, and eventually to other parts of the brain (Lehéricy et al., 1994; Scahill et al., 2002). Decades of research point towards $A\beta$ aggregation as an important contributor to AD pathogenesis. This could be due to either increased production of $A\beta$ or decreased clearance of $A\beta$. $A\beta$ oligomers are toxic in neuronal culture (Lambert et al., 1998), contribute to memory deficits in mice (Lesne et al., 2006), and correlate with neurodegeneration in AD patients (McLean et al., 1999). However, therapies targeting $A\beta$ have so far failed in clinical trials shifting the field towards studying

other contributing factors to AD pathogenesis, such as microbial infection (Fulop et al., 2018), dysfunctional vasculature (Zlokovic, 2011), and environmental pollution (Peters et al., 2019). Currently, AD treatments can treat the symptoms but fail to slow disease progression or cognitive decline.

1.2 Parkinson's disease (PD).

PD is the second most common neurodegenerative disease, affecting as many as 10 million individuals worldwide. PD is a movement disorder, which is characterized by the degeneration of dopaminergic neurons within the substantia nigra (SN) and the formation of aggregates, called Lewy bodies, which are primarily composed of a protein called α -synuclein. While interventions are available to control the motor symptoms of PD, there are currently no treatments that can prevent the loss of dopamine neurons or halt the progression of this disease. A growing number of genes have been shown to contribute to the development of PD including *SNCA*, the gene that encodes α -synuclein (Polymeropoulos et al., 1997; Singleton et al., 2003), and *LRRK2*, which encodes a Leucine-Rich Repeat Kinase (Paisan-Ruiz et al., 2004; Zimprich et al., 2004). Nonetheless, the majority of PD cases are considered to be sporadic, as only ~10% of patients have a direct genetic cause. Although the pathogenesis of PD is incompletely understood, aging is the greatest risk factor for the development of PD (Collier et al., 2011; Driver et al., 2009). Individuals typically do not develop PD until they are 50 years and older. The prevalence of PD is 0.3% in the general population but increases to 1% for those over 60 years, and 4% for those more than 80 years of age. A role for aging in PD is also suggested by the fact that there are many commonalities between PD and normal aging (Rodriguez et al., 2015) including protein aggregation (Tan et al., 2009), increased oxidative stress (Zhou et al., 2008), decreased mitochondrial function (Henchcliffe and Beal, 2008), dysfunction of the proteasome (Cook and Petrucelli, 2009), and impairment of autophagy (Pan et al., 2008).

1.3 Huntington's disease (HD).

HD is the most common inherited neurodegenerative disorder, affecting approximately one in 10,000 individuals. Unlike more widespread disorders, such as AD and PD, HD is entirely due to a single genetic cause: a trinucleotide CAG repeat expansion in the huntingtin (*HTT*) gene. HD is an autosomal dominant disorder which causes motor dysfunction, cognitive deficits, and neuropsychiatric abnormalities. In the brain, HD is characterized by selective degeneration of the striatum and the cortex as well as the appearance of mutant Htt aggregates. Following the discovery of the *HTT* gene, a number of genetic animal models of HD have been generated to study disease mechanisms and treatment (Brignull et al., 2006; Faber et al., 1999; Fernandez-Funez et al., 2000; Gray et al., 2008; Mangiarini et al., 1996; Marsh et al., 2000; Parker et al., 2001; Satyal et al., 2000; Schilling et al., 1999; Slow et al., 2003). Nonetheless, the pathogenesis of HD is not completely understood, and there are currently no approved disease-modifying therapies. An important unanswered question is why HD takes decades to develop when the disease-causing mutation is present in all cells throughout life. The average age of onset for HD is 40 years of age, progressing inevitably to death 10–15 years thereafter. A role for aging in the pathogenesis of HD is supported by the fact that multiple functions that decline with age have also been implicated in the disease including decreased proteasome activity, decreased autophagy, decreased chaperone

function, mitochondrial dysfunction, increased oxidative stress, and increased protein aggregation (Bence et al., 2001; Browne and Beal, 2006; DiFiglia et al., 1997; Kitamura et al., 2006; Panov et al., 2002; Ravikumar et al., 2004).

1.4 Amyotrophic lateral sclerosis (ALS).

ALS is the most common adult-onset motor neuron disease, affecting one in 50,000 people in Western countries (Chiò et al., 2013). ALS is caused by degeneration of upper and lower motor neurons, leading to loss of voluntary movement. The disease progresses swiftly, with patients succumbing to the disease within an average of three years after diagnosis (del Aguila et al., 2003). Roughly 95% of ALS cases are sporadic (Byrne et al., 2011), with the largest known risk factor for sporadic ALS being aging. Both sporadic and familial ALS-onset typically occurs between 40–70 years of age (Alonso et al., 2009). The cellular pathogenesis of ALS is unclear, but a cellular hallmark of ALS is cytoplasmic aggregates in the motor neurons of patients. Over 97% of sporadic ALS cases have aggregates containing the RNA/DNA binding proteins TAR DNA-binding protein 43 (TDP-43) or fused in sarcoma (FUS) (Deng et al., 2010; Neumann et al., 2006). Mutations in FUS or the TDP-43-encoding gene, transactive response DNA binding protein (TARDBP), can cause familial ALS (Guerrero et al., 2016), and have been used to generate animal models of the disease. Animal models of ALS have also been generated using aggregation-inducing mutations in superoxidase dismutase 1 (SOD1), as this is a common genetic cause of ALS in humans. However, SOD1 animal models and patients do not exhibit FUS aggregation, making it unclear if SOD1 ALS animals are an accurate model for sporadic ALS (Deng et al., 2010). Work with these ALS models and others have identified defects in RNA regulation, phase-separation, nucleocytoplasmic trafficking, stress granule regulation, selective autophagy, and cytoskeleton dynamics (Kim and Taylor, 2017; Taylor et al., 2016; Van Damme et al., 2017). It is unclear if one of these pathways is the driving cause of ALS or if they each contribute to ALS pathogenesis.

1.5 Targeting aging pathways as a therapeutic strategy for neurodegenerative disease.

While aging was traditionally considered to be a stochastic process of damage accumulation, it is now clear that lifespan is strongly influenced by genetics. Mutations in a single gene out of many thousand genes can increase lifespan in various model organisms including yeast, flies, worms and mice, and are associated with longevity in humans. Importantly, genes and interventions that increase lifespan in one species have been shown to be conserved across species (Friedman and Johnson, 1988; Holzenberger et al., 2003; Kenyon et al., 1993; Suh et al., 2008). Interestingly, these lifespan-extending genes have also been shown to be protective in animal models of neurodegenerative disease including AD (Cohen et al., 2006; Cohen et al., 2009; Freude et al., 2009; Killick et al., 2009), PD (Cooper et al., 2015; Knight et al., 2014), HD (Hsu et al., 2003; Jiang et al., 2012; Morley et al., 2002; Sadagurski et al., 2011), and ALS (Bocitto et al., 2012). This strongly suggests that targeting molecular pathways that modulate aging may be an effective strategy to treat neurodegenerative disease. Despite these exciting observations, it remains a challenge to translate genetic treatments to humans.

As an alternative, it may be possible to develop novel treatments for neurodegenerative diseases using compounds that modulate aging. In addition to identifying a plethora of genes that can affect longevity (<https://genomics.senescence.info/genes/>), aging research has also identified multiple compounds that extend lifespan in model organisms (<http://genomics.senescence.info/drugs/>). In this review, we examine the effects of five compounds that have been shown to modulate aging (metformin, resveratrol, rapamycin, N-acetyl-L-cysteine, and curcumin) in four neurodegenerative diseases (AD, PD, HD and ALS). We find that compounds that increase lifespan can be neuroprotective in models of neurodegenerative disease (Figure 1), and thus may represent a novel treatment strategy for these disorders.

2. Metformin

Metformin is a promising preventative treatment for age-associated diseases. Metformin is commonly used for treating Type 2 Diabetes Mellitus (T2DM), and retrospective studies discovered that metformin treatment of T2DM patients caused reduced incidents of age-associated diseases such as cardiovascular diseases (Campbell et al., 2017), cancers (Gandini et al., 2014; Wu et al., 2014), and neurodegenerative diseases (Cheng et al., 2014; Ng et al., 2014). In T2DM patients, metformin causes reduced glucose production in the liver, as well as increased insulin sensitivity in the peripheral tissues (Giannarelli et al., 2003). Metformin is delivered orally and disperses throughout the body to the liver, kidney, muscles, and the brain (Gormsen et al., 2016; Kulkarni et al., 2018; Labuzek et al., 2010), which may explain its widespread physiological effects. The specific molecular interactions of metformin are still unclear. However, metformin leads to activation of the highly conserved energy-sensing AMP-activated protein kinase (AMPK) pathway (Fullerton et al., 2013; Zhou et al., 2001). Metformin also independently activates mTORC1, which causes activation of AMPK through a lysosomal pathway (Kalender et al., 2010; Zhang et al., 2016). Activation of the AMPK pathway corrects energy imbalances by increasing lipid metabolism, increasing mitochondrial biogenesis, increasing autophagy, delaying cell cycle progression and decreasing protein production (Hardie et al., 2012). The AMPK pathway also modulates inflammation and inhibits the c-Jun N-terminal kinase (JNK) pathway (Chen et al., 2019; Hu et al., 2016). Therefore, metformin treatment regulates multiple pathways associated with aging.

2.1 Effect of metformin on lifespan

Metformin has mixed effects on lifespan in various model organisms (Table 1), but improves healthspan experimentally in murine models and is associated with decreases in age-related diseases in humans with T2DM. Metformin was first shown to extend lifespan in *C. elegans* (Onken and Driscoll, 2010), but, interestingly, this effect was due to metabolic changes in the bacterial food source, not the nematodes (Cabreiro et al., 2013). Subsequent studies were unable to demonstrate a beneficial effect of metformin on lifespan in *Drosophila* (Slack et al., 2012). In mice, metformin was shown to cause a small, but statistically significant, increase in lifespan (Martin-Montalvo et al., 2013). However, a larger study performed at multiple locations with genetically heterogenous mice failed to find a statistically significant increase in lifespan when animals were treated with metformin alone (Strong et al., 2016).

Nonetheless, metformin exhibits a more clearly beneficial effect on the healthspan of mice (Feng et al., 2020; Martin-Montalvo et al., 2013). This is consistent with previous research showing that metformin improves cardiovascular function and cognition in aging mice (Campbell et al., 2017; UKPDS, 1998). In retrospective cohort studies, metformin was associated with extended lifespan of T2DM patients (Bannister et al., 2014; Campbell et al., 2017). Based on these promising results, a large randomized controlled study has been planned to determine if metformin affects lifespan and healthspan in healthy humans (Barzilai et al., 2016).

2.2 Metformin and Alzheimer's disease

In the majority of studies reported, metformin is protective against dementia and AD in model organisms and in humans (Table 2). Treatment with metformin ameliorates phenotypic deficits in AD models in cell culture (Chen et al., 2016), *C. elegans* (Ahmad and Ebert, 2017), *Drosophila* (Niccoli et al., 2016), and mice (Chen et al., 2019; Farr et al., 2019; Ou et al., 2018). Metformin treatment after phenotypic onset improved behavioral phenotypes in APP/PS1 mice (Matthes et al., 2018) and in an STZ-induced AD rodent model (Nassar et al., 2018). In contrast, metformin treatment exacerbated motor and behavioral deficits in a P301S mutant human tau mouse model (Barini et al., 2016). Metformin treatment also increased tau phosphorylation in murine AD models expressing human ApoE3 or ApoE4 (Zhang et al., 2019). Interestingly, metformin still improved cognition in the ApoE3 mouse, but not the ApoE4 mice, suggesting that genetic differences can influence the efficacy of metformin in treating AD. Another cautionary note is that metformin can cause increased A β production, which is inhibited by insulin (Chen et al., 2009). In patients with T2DM, metformin treatment alone was associated with a decrease in the risk of dementia in multiple retrospective cohort studies (Bohlken et al., 2018; Cheng et al., 2014; Hsu et al., 2011; Orkaby et al., 2017; Shi et al., 2019). However, two studies did find that metformin treatment of T2DM patients was associated with an increased risk of developing AD (Imfeld et al., 2012; Kuan et al., 2017). Metformin has been proposed to be protective against AD by inhibiting the JNK pathway, causing suppression of cell death (Chen et al., 2016). It may also be protective through increasing glucose transport in neurons (Niccoli et al., 2016). While metformin has promising effects on AD models, more research needs to be done to determine why it has detrimental effects in certain systems.

2.3 Metformin and Parkinson's disease

Metformin may reduce the risk of developing PD (Table 3). Of three retrospective cohort studies, two found that metformin-treated T2DM patients had reduced risk of developing PD (Shi et al., 2019; Wahlqvist et al., 2012), while the other found an increased risk of developing PD (Kuan et al., 2017). Experimentally, metformin is protective in PD models in cell culture (Dulovic et al., 2014; Kang et al., 2017), *C. elegans* (Saewanee et al., 2019), *Drosophila* (Ng et al., 2012), and in mice (Kang et al., 2017; Lu et al., 2016). Metformin appears to be protective against PD through the activation of AMPK, though dopaminergic neurons do not need to have functioning AMPK for metformin to be protective (Bayliss et al., 2016). Several downstream targets of AMPK have been identified as possibly delaying PD symptoms, specifically inhibiting microglia overactivation (Lu et al., 2016) and activation of the PGC-1 α pathway, which stimulates mitochondrial biogenesis (Kang et al.,

2017). Interestingly, while metformin increases autophagy induction (Lu et al., 2016), autophagy is not required for the protective effects of metformin (Dulovic et al., 2014).

2.4 Metformin and Huntington's disease

Metformin consistently suppresses or delays HD phenotypic deficits in cell culture (Jin et al., 2016), *C. elegans* (Sanchis et al., 2019; Vázquez-Manrique et al., 2016), mice (Arnoux et al., 2018; Sanchis et al., 2019) and humans (Hervás et al., 2017) (Table 4). Most promisingly, diabetic HD patients treated with metformin exhibited improved cognitive functions compared to nondiabetic HD controls (Hervás et al., 2017). This delay of HD symptoms may be due to decreased translation of mutant HTT, the protein which drives HD disease progression (Arnoux et al., 2018; Sanchis et al., 2019). The protective effect of metformin may also be due to its ability to prevent mitochondrial depolarization as shown in mHTT striatal cell culture (Jin et al., 2016).

2.5 Metformin and amyotrophic lateral sclerosis

Based on the limited number of studies that have been reported, metformin has either negligible or exacerbating effects on ALS (Table 5). In the single experimental study identified, metformin treatment of SOD1(G93A) male mice caused no effect, while treatment of SOD1(G93A) female mice caused a decreased age of onset and increased rate of disease progression (Kaneb et al., 2011). A retrospective cohort study determined that metformin treatment had no effect on the progression of ALS in T2DM patients (Bond et al., 2020).

3. Resveratrol

Resveratrol (3,5,4'-trihydroxystilbene) is a polyphenol found in purple grapes, red wine and many plants. Its potential benefits were first manifested through the "French Paradox", which associated red wine consumption with decreased risk of cardiovascular diseases (Renaud and de Lorgeril, 1992). Although red wine content in resveratrol is insufficient to provide significant pharmacological effects (Vitaglione et al., 2005; Walle et al., 2004), resveratrol has been associated with many benefits such as anti-carcinogenic (Jang and Pezzuto, 1999), cardioprotective (Ungvari et al., 2007) and neuroprotective effects (Bastianetto et al., 2015).

The mechanism underlying its protection is not completely understood. The conserved NAD-dependent deacetylase sirtuin-1, SIRT1, and its invertebrate homologue SIR-2 were initially believed to mediate the lifespan-extending effect and protection conferred by resveratrol (Howitz et al., 2003; Viswanathan et al., 2005; Wood et al., 2004). However, these findings have been debated considering that sirtuin-independent lifespan extension was observed (Bass et al., 2007; Zhang, 2006) and that resveratrol did not directly affect SIRT1 activity (Behr et al., 2009; Kaeberlein et al., 2005; Pacholec et al., 2010). Furthermore, resveratrol activates AMP-activated kinase (AMPK) in both SIRT-1 dependent and independent manner (Dasgupta and Milbrandt, 2007; Price et al., 2012; Suchankova et al., 2009) Whether SIRT-1 is involved in the protective effects of resveratrol is yet to be confirmed. Other reported activities of resveratrol include reducing oxidative damage by

acting as an anti-oxidant (Li et al., 2014a), reducing neuroinflammation through inhibition of the NF κ B pro-inflammatory pathway (Das and Das, 2007; Manna et al., 2000; Zhang et al., 2010b), decreasing neuronal apoptosis via acetylation of p53 pro-apoptotic factor (Kim et al., 2007; Luo et al., 2001; Vaziri et al., 2001) and improving mitochondrial functions through PGC-1 α activation (Naia et al., 2017; Price et al., 2012).

3.1 Effect of resveratrol on lifespan

Resveratrol was first observed to extend lifespan in yeast (Howitz et al., 2003) and the same effect was later demonstrated in *C. elegans* (Bass et al., 2007; Gruber et al., 2007; Viswanathan et al., 2005; Wood et al., 2004), *Drosophila* (Bauer et al., 2004; Wood et al., 2004) and honey bees (Rascón et al., 2012) (Table 1). Lifespan extension by resveratrol in vertebrates was only observed in the fish *N. furzeri* (Valenzano et al., 2006), as resveratrol failed to extend lifespan in mice (Strong et al., 2013), except in mice that were placed on a high calorie diet (Baur et al., 2006). However, evidence from rodent studies suggest that resveratrol can increase neuronal cell viability (Albani et al., 2009) and delay onset of age-related diseases (Pearson et al., 2008). The mechanism underlying the lifespan-extending effect of resveratrol is mainly unknown, although some studies showed that this relies on AMPK activation and related changes in metabolism (Apfeld et al., 2004; Greer et al., 2007). While resveratrol increased lifespan in simple animal models, additional research will be required to determine why this effect was not observed in mammals.

3.2 Resveratrol and Alzheimer's disease

Resveratrol improves AD pathology in many studies (Table 2), but its mechanisms of action are unclear. Both rodent and cell line models of AD treated with resveratrol showed decreased amyloid- β aggregation and reduced cytotoxicity (Capiralla et al., 2012; Huang et al., 2011; Karuppagounder et al., 2009; Marambaud et al., 2005; Porquet et al., 2013; Vingtdoux et al., 2010; Zhao et al., 2015). The same effect was also observed in *C. elegans* (Regitz et al., 2016). Moreover, tau hyperphosphorylation was found to be reduced by resveratrol treatment (Lin et al., 2018; Porquet et al., 2013; Schweiger et al., 2017), along with reduced levels of oxidative damage (Granzotto and Zatta, 2011; Huang et al., 2011; Lin et al., 2018). These effects appear to be mediated by an increased production of antioxidants such as heme oxygenase-1 (HO-1) and glutathione (GSH) through the Nrf2 pathway (Chen et al., 2005; Huang et al., 2011; Kong et al., 2019; Sharma and Gupta, 2002). Additionally, SIRT1 activation is believed to mediate many of the beneficial effects of resveratrol on AD impairments (Cristòfol et al., 2012; Porquet et al., 2013) and might act through reducing neuronal apoptosis (Feng et al., 2013; Kim et al., 2007). Resveratrol can also promote A β clearance through the AMPK pathway (Porquet et al., 2013; Vingtdoux et al., 2010). Furthermore, resveratrol treatment decreased neuroinflammation in rodent models (Capiralla et al., 2012; Gong et al., 2010), as well as in a recent clinical trial conducted on AD patients (Moussa et al., 2017). However, other human studies have shown mixed results (Moussa et al., 2017; Turner et al., 2015; Zhu et al., 2018). Together, these findings show a protective effect of resveratrol in AD models, while further human clinical trials will be necessary to determine the efficacy of resveratrol for AD treatment.

3.3 Resveratrol and Parkinson's disease

Resveratrol improves PD-associated impairments in various PD rodent models (Table 3), including the 6-OHDA rat model (Jin et al., 2008; Khan et al., 2010) and the MPTP-treated mouse model (Blanchet et al., 2008; Liu et al., 2019; Wang et al., 2015; Xia et al., 2019). A decrease in α -synuclein aggregation, dopamine loss and oxidative stress was observed after resveratrol treatment (Gaballah et al., 2016; Khan et al., 2010; Zhang et al., 2018), along with reduced neuroinflammation (Jin et al., 2008; Liu et al., 2019; Lofrumento et al., 2014). The specific mechanism by which resveratrol exerts its effects in PD is still unknown. However, resveratrol was shown to act through enhanced autophagy (Ferretta et al., 2014; Wu et al., 2011), decreased apoptosis (Alvira et al., 2007; Xia et al., 2019) and mitochondrial biogenesis (Ferretta et al., 2014). These improvements require AMPK and SIRT1 activation (Ferretta et al., 2014; Wu et al., 2011), as well as the SIRT1 target PGC-1 α (Ferretta et al., 2014). Combined these studies demonstrate a potential protective role of resveratrol in PD.

3.4 Resveratrol and Huntington's disease

HD-associated phenotypes such as neuronal degeneration were reduced by resveratrol treatment in many HD animal models, including *C. elegans* (Parker et al., 2005), *Drosophila* (Maher et al., 2011; Pallos et al., 2008) and multiple rodent models (Ho et al., 2010; Naia et al., 2017) (Table 4). Similar to PD models, resveratrol treatment in HD models is believed to act through SIRT1 to increase neuronal viability (Ho et al., 2010; Naia et al., 2017; Parker et al., 2005). Furthermore, SIRT1 activation by resveratrol may increase PGC-1 α expression (Ho et al., 2010; Naia et al., 2017). PGC-1 α is involved in mitochondrial biogenesis and functions, and its reduced expression may contribute to the mitochondrial defects in HD (Naia et al., 2017). Therefore, PGC-1 α might mediate some of the protective effects of resveratrol in HD models.

3.5 Resveratrol and amyotrophic lateral sclerosis

Research on the effects of resveratrol in ALS is scarce. A first report in ALS cell lines and SOD1 mouse models showed increased neuronal survival and decreased neurodegeneration after treatment with resveratrol (Kim et al., 2007; Mancuso et al., 2014). Additionally, activation of SIRT1 and reduced acetylation of p53 were observed (Kim et al., 2007; Mancuso et al., 2014), as well as the activation of AMPK (Mancuso et al., 2014). These findings indicate that resveratrol may be protective in ALS (Table 5), through the same mechanisms that are proposed to contribute to protection in other neurodegenerative diseases.

4. Rapamycin

Rapamycin, also known as sirolimus, is an inhibitor of the evolutionarily conserved target of rapamycin (TOR). It is an anti-fungal metabolite produced by *Streptomyces hygroscopicus* (Li et al., 2014b). Rapamycin inhibits TOR activity by acting as a “lynchpin” in a molecular interaction between TOR and FKBP12 that impedes TOR from phosphorylating its downstream targets (Choi et al., 1996; Stan, 1994; Stanfel et al., 2009). TOR is active in target of rapamycin complex 1 and 2 (TORC1 and TORC2), which together act as key

regulators of cellular metabolism and growth (Stanfel et al., 2009). It is thought that the benefits of short-term doses of rapamycin are due to TORC1 inhibition (Stanfel et al., 2009), resulting in several changes including inhibition of protein synthesis and stimulation of autophagy (Kapahi et al., 2010; Stanfel et al., 2009).

4.1 Effect of rapamycin on lifespan

Rapamycin treatment increases lifespan in *C. elegans* (Robida-Stubbs et al., 2012), *Drosophila* (Bjedov et al., 2010), and mice (Fok et al., 2014; Harrison et al., 2009; Miller et al., 2011; Wilkinson et al., 2012; Zhang et al., 2014) (Table 1). Interestingly, rapamycin has also been reported to increase immune function in older humans and it has been suggested that it could be used to ameliorate immunosenescence in the elderly population (Mannick et al., 2014; Mannick, 2018). Increased mTOR activity has been implicated in multiple hallmarks of aging, including deregulated protein synthesis and decreased autophagy (Johnson et al., 2013; Kapahi et al., 2010; Laplante and Sabatini, 2012). One way in which rapamycin is thought to slow aging is by reducing protein synthesis via TORC1 inhibition (Lamming et al., 2013). Inhibition or loss of the TORC1 effector, ribosomal S6 kinase (S6K), has been shown to enhance longevity by reducing translation initiation in model organisms (Hansen et al., 2007; Kapahi et al., 2004; Pan et al., 2007; Selman et al., 2009). Furthermore, studies in *C. elegans* show that inhibition of the cap-dependent eukaryotic translation initiation factor 4E (eIF4E) plays a significant role in increasing lifespan through TORC1 inhibition (Hansen et al., 2007; Pan et al., 2007; Syntichaki et al., 2007). Rapamycin treatment may therefore reduce cap-dependent translation, thereby increasing cap-independent translation, which may allow for expression of stress-response genes (Bjedov et al., 2010). Rapamycin is also thought to slow aging by stimulating autophagy (Lamming et al., 2013). TORC1 inhibition results in increased levels of AMPK-activated ULK1 and ATG13 (Laplante and Sabatini, 2009), which, together, initiate autophagosome formation and allow for clearance of accumulated material in the cell (Ganley et al., 2009; Kim et al., 2011).

4.2 Rapamycin and Alzheimer's disease

Activation of the downstream effectors of TOR is increased in AD models, suggesting that over-active TORC1 could be contributing to pathology in AD brains (An, 2003; Griffin et al., 2005; Li, 2004; Pei et al., 2006). In *Drosophila* AD models, rapamycin treatment results in decreased levels of tau toxicity, apoptotic neurons, neurodegenerative markers and increased survival (Berger et al., 2006; Khurana et al., 2006). Studies in both PDAPP and 3xTg-AD mouse models have also reported reduced A β and tau toxicity as well as amelioration of cognitive deficits in response to rapamycin treatment (Caccamo et al., 2010; Majumder et al., 2011; Spilman et al., 2010). Additionally, in hAPP(J20) mice, rapamycin protected the blood brain barrier, which is often critically disrupted in AD (Van Skike et al., 2018). However, studies with cells expressing human APP and studies with Tg2576 mice suggest that inhibition of mTORC1 by rapamycin can also exacerbates A β toxicity (Yu et al., 2005; Zhang et al., 2010c). Together, these findings suggest that rapamycin may be able to attenuate AD phenotypes (Table 2), but further studies are required to determine why, in certain AD models, rapamycin may augment A β toxicity.

4.3 Rapamycin and Parkinson's disease

Both increased mTOR activity and reduced autophagy are seen in mouse PD models and in patients with dementia with Lewy bodies (DLB) (Crews et al., 2010). The effects of rapamycin in PD models have largely been linked to reduced translation initiation via S6K and eIF4E as well as recovery of autophagy levels, both mediated by TORC1 inhibition (Bove et al., 2011). Treatment with rapamycin improves neurodegenerative phenotypes seen in PD models of *Drosophila* (Table 3), including climbing ability and survival of dopaminergic neurons. It was also shown in *Drosophila* that 4E-binding protein (4E-BP), a downstream effector of TOR and inhibitor of translation initiation factor eIF4E, is required for rapamycin protection (Tain et al., 2009). Furthermore, rapamycin reduces α -synuclein accumulation in neurons, improves lysosomal function and reduces neurodegeneration in C57BL/6 mice expressing human α -synuclein (D-line tg mice) (Crews et al., 2010). Additionally, in mice and human dopaminergic neuroblastoma cells treated with parkinsonian toxins, rapamycin enhanced autophagy and protected against death of neurons (Dehay et al., 2010; Malagelada et al., 2010). Rapamycin also improved memory deficits and depressive and anxiety-like behaviours in murine models (Masini et al., 2018), illustrating its ability to rescue both molecular and behavioural markers of PD.

4.4 Rapamycin and Huntington's disease

The putative role of mTOR in HD is demonstrated by the observations that overexpression of mutant Htt enhances mTORC1 activity in mouse striatal cells and HEK293 cells, and that enhanced mTORC1 activity in the striatum of HD mice results in premature death and severe motor defects (Pryor et al., 2014). Rapamycin reduces mutant Htt aggregates in *Drosophila*, in the N171–82Q mouse model, and in mammalian cells expressing exon 1 of the mutant HD gene with disease-length polyglutamine expansion (King et al., 2008; Ravikumar et al., 2004; Ravikumar, 2002). Both *Drosophila* and mouse models of HD also show improved motor function with rapamycin treatment (Ravikumar et al., 2004) (Table 4). Proposed mechanisms of action include both induction of autophagy and reduction of protein synthesis (King et al., 2008; Ravikumar et al., 2004; Ravikumar, 2002). However, other studies suggest that while rapamycin may reduce protein synthesis and improve motor function, it may also have no effect on mutant Htt levels and may not be neuroprotective in R6/2 mouse models of HD (Fox et al., 2010). Therefore, while rapamycin acted as a promising therapeutic in many HD models, further studies should be conducted to distinguish between rapamycin's effects on motor function and mutant Htt in mouse models.

4.5 Rapamycin and amyotrophic lateral sclerosis

Rapamycin increases survival and suppresses locomotor deficits in TDP-43 *Drosophila* models of ALS (Cheng et al., 2015) (Table 5). Similarly, in murine TDP-43 models of ALS, rapamycin treatment also reduced neuronal death, reduced accumulation of abnormal TDP-43 and reduced loss of motor functions (Wang et al., 2012). Studies in TDP-43 cell lines also report that rapamycin reduces abnormal TDP-43 (Caccamo et al., 2009). Notably, in all TDP-43 animal models of ALS, there is strong evidence that the activation of autophagy mediates the therapeutic effects seen with rapamycin treatment (Caccamo et al., 2009; Cheng et al., 2015; Wang et al., 2012). In contrast, in SOD1 murine models of ALS, it

has been observed that rapamycin does not reduce neuronal death, nor does it increase survival (Staats, 2013; Zhang et al., 2011). It is important to note that SOD1 mouse models do not display TDP-43 aggregation (Turner et al., 2008) and that TDP-43 aggregates are seen in most sporadic ALS cases (Prasad et al., 2019), suggesting that the SOD1 mouse model may not be representative of the pathology seen in the majority of ALS cases (Turner et al., 2008). Rapamycin has been recognized as a promising therapeutic for ALS patients and currently, a clinical trial in Italy is investigating rapamycin and riluzole as a potential combination therapy (Mandrioli et al., 2018).

5. N-acetyl cysteine

N-acetyl-*L*-cysteine (NAC) is a thiol, a mucolytic agent and an antioxidant. Most commonly known as a treatment for acetaminophen toxicity, NAC has a wide range of clinical applications primarily due to its ability to act as an antioxidant (Dekhuijzen, 2004). Despite its widespread use, how NAC acts as an antioxidant is still unclear. While it was originally believed that NAC scavenges oxidants such as hydrogen peroxide (H₂O₂) and superoxide (O₂^{·-}) by using its thiol group to reduce them, it has been suggested that the rate constants of these reactions are too low for this to be likely (Ezerina et al., 2018). Instead, it has been proposed that NAC derives most of its antioxidant properties from being a cysteine precursor, resulting in elevated synthesis of glutathione (GSH), a critical and ubiquitous thiol antioxidant (Arakawa and Ito, 2007). GSH contributes to enzymatic and non-enzymatic antioxidant systems and is thus important for protection against many toxins (Bump and Brown, 1990). NAC also protects cells from apoptosis by activating extracellular signal-related kinase pathways (Zafarullah et al., 2003). Thus, NAC acts as an antioxidant through its capacity as a free radical scavenger and as a cysteine precursor, elevating intracellular concentrations of GSH.

5.1 Effect of N-acetyl cysteine on lifespan

NAC has been shown to increase longevity in various model organisms (Table 1). In *C. elegans*, NAC treatment at 5 mM increases mean lifespan by up to 30.5% (Oh et al., 2015), while increased concentrations of 10 mM cause a smaller increase of mean lifespan (Yang and Hekimi, 2010). In *Drosophila*, NAC significantly increases median lifespan by up to 26.6% at 10 mg/ml concentrations (Brack et al., 1997), while higher concentrations are toxic leading to a significant decrease in lifespan (Niraula and Kim, 2019). The effect of NAC treatment in mice is sex-dependent, as it increases mean lifespan in males but not in females (Flurkey et al., 2010). It is important to note however that mice treated with NAC exhibit reduced food intake which is also shown to increase lifespan in mice (Flurkey et al., 2010). Hence, it is possible that dietary restriction contributes to NAC's effect on lifespan in mice.

5.2 N-acetyl cysteine and Alzheimer's Disease

NAC protects against A β -induced apoptosis in cultured cortical neurons by stimulating p35/Cdk5-mediated synaptic plasticity (Hsiao et al., 2008) and reducing JNK activity (Xu et al., 2009) (Table 2). NAC may also help protect against the neuro-inflammatory aspect of AD by increasing intracellular concentrations of GSH in glial cells and astrocytes (Tardiolo et al., 2018). In A β -injected and streptozotocin-induced rodent AD models, NAC treatment

alleviates AD-induced cognitive deficits (Costa et al., 2016; Shahidi et al., 2017) by restoring the cortical and hippocampal cholinergic system and alleviating of oxidative stress (Huang et al., 2010; Prakash et al., 2015; Tchantchou et al., 2005). Clinical trials of NAC as a treatment for AD have yielded insignificant and mixed results (Deepmala et al., 2015). The largest controlled trial reports favourable changes in almost all cognitive outcome measures when patients were treated with NAC; however, only a few changes were significant (Adair et al., 2001). Additional trials with greater sample sizes would be needed to determine if NAC can act as an AD treatment.

5.3 N-acetyl cysteine and Parkinson's Disease

NAC is protective in both animal models of PD, and PD patients (Table 3). PD is associated with decreased GSH concentration in the substantia nigra, potentially due to mitochondrial dysfunction and oxidative stress (Bavarsad Shahripour et al., 2014). NAC treatment significantly increases the survival of iPSC-derived dopaminergic neurons treated with rotenone to model PD (Monti et al., 2016). NAC treatment of rotenone-induced PD murine models protects against motor deficits and loss of dopaminergic neurons (Rahimmi et al., 2015). In murine models, it is thought that protection of dopaminergic neurons is mediated by the antioxidant capacity of NAC. Thus, increasing GSH synthesis may be protecting against α -synuclein toxicity (Clark et al., 2010). In preliminary human trials, NAC treatment caused a decrease in clinical symptoms of PD and an increase in dopamine transporter binding, which is impaired in PD (Monti et al., 2016).

5.4 N-acetyl cysteine and Huntington's Disease

Preliminary data suggests that NAC treatment is protective in HD models due to its ability to counter oxidative stress and mitochondrial dysfunction, which both contribute significantly to HD pathogenesis (Li et al., 2010; Sandhir et al., 2012; Stack et al., 2008) (Table 4). Chronic NAC administration is protective in the R6/1 mouse model of HD. Treatment delays the onset of HD-associated motor deficits, and, through cysteine supplementation, improves the glutamatergic dysfunction that underlies depressive behavior in HD (Wright et al., 2015).

5.5 N-acetyl cysteine and amyotrophic lateral sclerosis

NAC is protective in certain models of ALS, however, it has no significant effect in human ALS patients (Table 5). In human neuroblastoma SH-SY5Y cells expressing mutant SOD1 (G93A), increased cytosolic and mitochondrial ROS production is observed (Beretta et al., 2003). NAC treatment reverses the observed mitochondrial impairment (Beretta et al., 2003). Furthermore, NAC treatment of SOD1 transgenic mice improved survival and delayed onset of motor deficits (Andreassen et al., 2000). Despite promising results in ALS models, clinical trials testing NAC as a potential treatment for ALS have been less successful. ALS patients show no significant difference in neuronal survival and/or disease progression with NAC treatment (Deepmala et al., 2015).

6. Curcumin

Curcumin is an extract from the spice turmeric, which belongs to the ginger family. Curcumin has been commonly used in herbal medicine in Asia for its anti-inflammatory,

antioxidant, and analgesic properties (Hewlings and Kalman, 2017). Therefore, it has been studied as a potential therapeutic for various diseases and conditions (Gupta et al., 2013). Curcuminoids, which includes curcumin and its related compounds such as tetrahydrocurcumin, demethoxycurcumin and bis-demethoxycurcumin have also been tested as longevity-promoting compounds. Curcumin acts through various mechanisms; it decreases levels of reactive oxygen species (ROS) (Dai et al., 2018; Maugeri et al., 2018; Tapia et al., 2014) and has a variety of immunomodulatory activities, such as regulating B-cells, T cells and macrophage activities (Churchill et al., 2000; Yadav et al., 2005). Curcumin also reduces pro-inflammatory cytokines (Jin et al., 2007; Panahi et al., 2016), potentially through inhibition of the NF- κ B inflammatory pathway (Singh and Aggarwal, 1995). Additionally, curcumin also affects epigenetic regulation of gene expression by methods such as inhibiting DNA methylation (Liu et al., 2009) and increasing histone acetylation (Chen et al., 2007; Liu et al., 2005). While studies investigating the lifespan and neuroprotective effects of curcumin show a beneficial effect, it is important to note that these studies are relatively sparse compared to studies on other compounds discussed, and further research needs to be conducted.

6.1 Effect of curcumin on lifespan

Curcumin generally increases lifespan in the animal models tested (Table 1). In *C. elegans*, curcumin increases lifespan as well as increases resistance to oxidative stress (Liao et al., 2011). A recent study using a synthetic curcumin derivative, Cur2004–8, was also found to increase lifespan and increase resistance to oxidative stress to an even greater extent than curcumin. Curcumin also extends the lifespan of *Drosophila* (Chandrashekara et al., 2014; Lee et al., 2010; Shen et al., 2013; Soh et al., 2013; Suckow and Suckow, 2006), potentially due to the increased resistance to oxidative stress, heat stress and irradiation (Chen et al., 2018; Lee et al., 2010; Seong et al., 2015). The curcumin derivative tetrahydrocurcumin has been tested in mice and showed mixed results; one smaller study showed increased lifespan when treatment was given at 13 months of age whereas a subsequent larger study using a lower concentration showed no effect on lifespan when treatment was started at 4 months of age (Kitani et al., 2007; Strong et al., 2013). Because many parameters differed between the two studies (dose, age of intervention, strain of mice, site), it is unclear why the latter study failed to reproduce the effect on lifespan.

6.2 Curcumin and Alzheimer's disease

Curcumin is protective in the AD models tested (Table 2). Curcumin treatment protects against A β -induced toxicity and increases oxidative stress in neuroblastoma, endothelial and rat PC12 culture (Kim et al., 2001; Qian et al., 2018). Curcumin can also affect A β formation (Ono et al., 2004) and metabolism (Zhang et al., 2010a), as well as reduce levels of A β by attenuating the maturation of the precursor protein (Zhang et al., 2010a). Additionally, curcumin decreases activation of microglia and astrocytes (Liu et al., 2016) which is another hallmark of AD. Curcumin treatment on peripheral blood mononuclear cells (PBMCs) derived from AD patients showed a decrease in A β levels compared to PBMCs without curcuminoid treatment (Gagliardi et al., 2018). In a recent study, a synthetic curcumin derivative, Cur2004–8, decreased A β -induced toxicity in a *C. elegans* model of AD (Kim et al., 2019). In a *Drosophila* AD model, various curcuminoids rescue eye

morphology and locomotor defects (Wang et al., 2014). Similarly, in rodents, curcumin decreases A β levels and plaque burden (Garcia-Alloza et al., 2007; Hamaguchi et al., 2009; Lim et al., 2001; Yang et al., 2005). Oxidative damage is also reduced with curcumin treatment of rodent models of AD, as indicated by a decrease in oxidized proteins (Lim et al., 2001). Curcumin also reduces pro-inflammatory cytokines and reduces activation of microglia and astrocytes in rodent models of AD (Begum et al., 2008; Liu et al., 2016; Sundaram et al., 2017). Cognitive performance in rodents was also improved with curcumin (Cheng et al., 2013; Frautschy et al., 2001; Ma et al., 2009). Curcumin and curcuminoid treatment were found to suppress the loss of synapses in AD rodent models (Ahmed et al., 2010; Frautschy et al., 2001; Garcia-Alloza et al., 2007). To date, only a few clinical trials have examined the effect of curcumin on AD patients, two of which found no changes in serum A β levels or improvement in cognitive ability (Baum et al., 2008; Ringman et al., 2012).

6.3 Curcumin and Parkinson's disease

Curcumin is generally protective in the PD models tested (Table 3). Oxidative stress is strongly associated with PD. Curcumin protects against oxidative stress through reducing lipid oxidation and reducing levels of malondialdehyde (Rascón et al.), H₂O₂ and ROS in a glutathione-depleted dopaminergic cell line and in a human neuroblastoma cell line (Harish et al., 2010; van der Merwe et al., 2017). Importantly, curcumin pre-treatment rescued cell viability and reduced apoptosis in a human neuroblastoma cell line, possibly through inhibiting caspase-3 (van der Merwe et al., 2017). Curcumin was also found to reduce toxicity by inhibiting apoptosis (Qualls et al., 2014; Sang et al., 2018). Lastly, curcumin and curcuminoids can increase α -synuclein degradation by preventing α -synuclein fibrillization and reducing α -synuclein aggregation (Gadad et al., 2012; Jiang et al., 2013). In various *Drosophila* models of PD, curcumin improved locomotor activity, reduced oxidative stress, and rescued dopaminergic neurons in the brain (Nguyen et al., 2018; Pandareesh et al., 2016; Siddique et al., 2014). In a rodent 6-hydroxydopamine (6-OHDA) model of PD, curcumin treatment protected against loss of TH+ cells and dopamine levels (Du et al., 2012; Zbarsky et al., 2005). Other models such as the Park7 (DJ-1) knockout model, the copper intoxication model, and the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model also found that curcumin protected against neuronal apoptosis and improved motor deficits (Abbaoui et al., 2017; Chiu et al., 2013; Pan et al., 2012). Other studies in rodent PD models support the antioxidant role (Khatri and Juvekar, 2016; Wang et al., 2017) and anti-inflammatory role (Sharma and Nehru, 2018) of curcumin.

6.4 Curcumin and Huntington's disease

Curcumin is beneficial in models of HD (Table 4). Curcumin protects against polyQ-mediated photoreceptor neuron degeneration and locomotor dysfunction in *Drosophila* models of HD (Chongtham and Agrawal, 2016; Ringman et al., 2012). In a CAG140 knockin mouse model of HD, curcumin protects the striatum, and rescues rearing behaviour (Hickey et al., 2012). In an R6/2 mouse model of HD, curcumin also protects the striatum, reduces mHtt levels and improves motor function (Elifani et al., 2019).

6.5 Curcumin and amyotrophic lateral sclerosis

Curcumin is protective in ALS models (Table 5). Using a motor neuron-like cell model of ALS (NCS-34 transfected with TDP-43), curcumin treatment rescued the abnormal excitability in the cells, such as higher firing frequency and lower threshold of action potential (Dong et al., 2014). In a clinical study, curcumin prevented the decline of motor functions as measured by the ALS Functional Rating Scale (ALS-FRS-r). The treatment group also showed improved ability to handle oxidative stress (Chico et al., 2018). Lastly, curcumin treatment significantly improved survival in patients who were also taking riluzole, compared to patients who were only taking riluzole alone (Ahmadi et al., 2018). However, other functional measures such as ALSFRS-R score, and muscle strength did not differ between the groups (Ahmadi et al., 2018).

7. Discussion

Metformin, resveratrol, rapamycin, NAC, and curcumin all increase lifespan in *C. elegans*, and all but metformin also increase lifespan in *Drosophila* (Table 1). In mice, the effect of these compounds on lifespan is more complicated, except for rapamycin, which has the most reproducibly beneficial effect on mouse longevity. While both metformin and curcumin have been shown to increase lifespan in mice, other studies have failed to reproduce this finding. In the case of NAC, it may be acting indirectly by decreasing food consumption thereby leading to dietary restriction. Resveratrol has only been shown to increase lifespan in mice maintained on a high fat diet. While examining the effects of these compounds on lifespan in mice has produced mixed results, the fact that at least one study has observed a significant increase in lifespan for each compound demonstrates that all of these compounds can increase lifespan in mammals, but, in some cases only under certain experimental conditions (dose, environment, strain, diet, etc.). Additional studies would be required to determine the precise reasons why the compounds increase lifespan in one experiment but not another, but these studies are time consuming and costly to perform in mice. Currently, it remains unknown whether these compounds can affect longevity in healthy humans.

Similar to their effect on longevity, the effect of these lifespan-extending compounds in models of neurodegenerative disease is more complicated in mammals than in simpler model organisms. Metformin, resveratrol, rapamycin, NAC and curcumin have all been shown to improve deficits in cellular, *C. elegans* and *Drosophila* models of neurodegenerative diseases (Tables 2–5). Although many studies support the beneficial effects of these compounds in rodents, and in some cases humans, other studies fail to show a benefit. In cases where a compound fails to show a benefit, the reasons for failure are often unclear. It is possible that a difference in one or more of the experimental conditions can account for the contradictory results. However, without further experimentation, it is hard to determine which factors if any are responsible for the differing outcomes. When an experiment does not reproduce a beneficial effect observed by others, it could simply be that the experiment failed for one of the several possible reasons when a compound and a complex organism are involved (e.g. wrong dose of compound, compound doesn't reach target tissue, compound delivery began at the wrong time point, experimenter error etc.). At

the same time, it is also possible that neutral or negative studies are not published leading to a reporting bias.

To better understand why differing results are sometimes obtained, it may be important to elucidate the precise mechanisms by which the lifespan-extending compounds are providing protection. One important question would be to determine how the neuroprotective effects of these compounds are related to their effects on aging. While we have hypothesized a simple relationship in which aging contributes to neurodegeneration and these compounds are neuroprotective because they delay aging, it is also possible that these compounds impact aging and neurodegeneration independently. Another possibility is that neurodegeneration is part of the aging process such that any impact that these compounds have on aging will necessarily also affect neurodegeneration.

The fact that each of the lifespan-extending compounds reviewed here can be protective in multiple different neurodegenerative diseases suggests the possibility that by targeting the aging process it may be possible to delay or prevent multiple diseases simultaneously. The idea of targeting aging as a cause of disease rather than studying individual diseases is the focus of the growing field of geroscience (Kennedy et al., 2014). As in the neurodegenerative diseases discussed here, aging is the main risk factor for a multitude of diseases, including cardiovascular disease and many forms of cancer. The goal of geroscience is to gain insight into the aging process and use that knowledge to delay or prevent changes that take place during normal aging. By intervening in the aging process, a single treatment may have a beneficial effect on a wide range of diseases in which aging contributes to disease pathogenesis.

8. Conclusions

In this review, we have shown that five different compounds that increase lifespan can be protective in four different neurodegenerative diseases. This suggests the possibility that compounds that increase lifespan may provide novel treatment strategies for these devastating disorders. For this to happen, it will be important to determine why these compounds are neuroprotective in some studies but not others, and why the beneficial effects have not, for the most part, translated into humans. In addition to the compounds reviewed here, there are a number of other compounds that have been shown to extend longevity, many of which have also been shown to be protective in models of neurodegenerative disease. Screening these compounds in cell culture and invertebrate models of neurodegenerative disease would allow for a rapid and cost-effective means to prioritize lifespan-extending compounds for further study in mammals.

Acknowledgements

This work was supported by the Canadian Institutes of Health Research (CIHR), the Natural Sciences and Engineering Research Council of Canada (NSERC), the Canadian Foundation for Innovation (CFI), the Fonds de Recherche Quebec Santé (FRQS), and the National Institutes of General Medical Sciences (NIGMS).

Abbreviations

4E-BP

4E-binding protein

6-OHDA

6-hydroxydopamine

AD

Alzheimer's disease

A β

Amyloid beta

ALS

amyotrophic lateral sclerosis

AMPK

AMP-activated protein kinase

APP

Amyloid precursor protein

ApoE3

Apolipoprotein E3

ApoE4

Apolipoprotein E4

ATG13

Autophagy Related 13

DLB

Dementia with Lewy bodies

eIF4E

Eukaryotic Translation Initiation Factor 4E

FKBP12

12 kDa FK506-binding protein

FUS

Fused in sarcoma

GSH

Glutathione

HD

Huntington's disease

HO-1

heme oxygenase-1

Htt

huntingtin

JNK

c-Jun N-terminal kinase

LRRK2

Leucine-Rich Repeat Kinase

MDA

malondialdehyde

MPP+1-methyl-4-phenylpyridinium

MPTP1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

mTOR

mammalian target of rapamycin

NAC

N-acetyl-L-cysteine

PCG-1 α

Peroxisome proliferator-activated receptor gamma coactivator 1-alpha

PD

Parkinson's disease

ROS

reactive oxygen species

S6K

Ribosomal protein S6 kinase

SIRT1

sirtuin-1

SN

substantia nigra

SNCA

synuclein alpha

SOD1

Superoxide dismutase 1

T2DM

Type 2 Diabetes Mellitus

TDP-43

TAR DNA-binding protein 43

TOR

target of rapamycin

TORC1

Target of rapamycin complex 1

TORC2

Target of rapamycin complex 2

ULK1

Unc-51 Like Autophagy Activating Kinase 1

References

- Abbaoui A, Chatoui H, El Hiba O, Gamrani H, 2017 Neuroprotective effect of curcumin-I in copper-induced dopaminergic neurotoxicity in rats: A possible link with Parkinson's disease. *Neurosci Lett* 660, 103–108. [PubMed: 28919537]
- Adair JC, Knoefel JE, Morgan N, 2001 Controlled trial of N-acetylcysteine for patients with probable Alzheimer's disease. *Neurology* 57, 1515–1517. [PubMed: 11673605]
- Ahmad W, Ebert PR, 2017 Metformin Attenuates A β Pathology Mediated Through Levamisole Sensitive Nicotinic Acetylcholine Receptors in a *C. elegans* Model of Alzheimer's Disease. *Mol Neurobiol* 54, 5427–5439. [PubMed: 27596506]
- Ahmadi M, Agah E, Nafissi S, Jaafari MR, Harirchian MH, Sarraf P, Faghihi-Kashani S, Hosseini SJ, Ghoreishi A, Aghamollai V, Hosseini M, Tafakhori A, 2018 Safety and Efficacy of Nanocurcumin as Add-On Therapy to Riluzole in Patients With Amyotrophic Lateral Sclerosis: A Pilot Randomized Clinical Trial. *Neurotherapeutics* 15, 430–438. [PubMed: 29352425]
- Ahmed T, Enam SA, Gilani AH, 2010 Curcuminoids enhance memory in an amyloid-infused rat model of Alzheimer's disease. *Neuroscience* 169, 1296–1306. [PubMed: 20538041]
- Albani D, Polito L, Batelli S, De Mauro S, Fracasso C, Martelli G, Colombo L, Manzoni C, Salmona M, Caccia S, Negro A, Forloni G, 2009 The SIRT1 activator resveratrol protects SK-N-BE cells from oxidative stress and against toxicity caused by α -synuclein or amyloid- β (1–42) peptide. *Journal of Neurochemistry* 110, 1445–1456. [PubMed: 19558452]
- Alonso A, Logroscino G, Jick SS, Hernan MA, 2009 Incidence and lifetime risk of motor neuron disease in the United Kingdom: a population-based study. *Eur J Neurol* 16, 745–751. [PubMed: 19475756]
- Alvira D, Yeste-Velasco M, Folch J, Verdaguer E, Canudas AM, Pallàs M, Camins A, 2007 Comparative analysis of the effects of resveratrol in two apoptotic models: inhibition of complex I and potassium deprivation in cerebellar neurons. *Neuroscience* 147, 746–756. [PubMed: 17583434]
- An WLC,R; Li L; Braak H; Alafuzoff I; Iqbal K; Iqbal IG; Winblad B; Pei JJ , 2003 Up-Regulation of Phosphorylated/Activated p70 S6 Kinase and Its Relationship to Neurofibrillary Pathology in Alzheimer's Disease. *American Journal of Pathology* 163, 591–607. [PubMed: 12875979]
- Andreassen OA, Dedeoglu A, Klivenyi P, Beal MF, Bush AI, 2000 N-acetyl-L-cysteine improves survival and preserves motor performance in an animal model of familial amyotrophic lateral sclerosis. *Neuroreport* 11, 2491–2493. [PubMed: 10943709]
- Apfeld J, O'Connor G, McDonagh T, DiStefano PS, Curtis R, 2004 The AMP-activated protein kinase AAK-2 links energy levels and insulin-like signals to lifespan in *C. elegans*. *Genes & development* 18, 3004–3009. [PubMed: 15574588]
- Arakawa M, Ito Y, 2007 N-acetylcysteine and neurodegenerative diseases: Basic and clinical pharmacology. *The Cerebellum* 6, 308–314. [PubMed: 17853088]
- Arnoux I, Willam M, Griesche N, Krummeich J, Watari H, Offermann N, Weber S, Narayan Dey P, Chen C, Monteiro O, Buettner S, Meyer K, Bano D, Radyushkin K, Langston R, Lambert JJ, Wanker E, Methner A, Krauss S, Schweiger S, Stroh A, 2018 Metformin reverses early cortical

network dysfunction and behavior changes in Huntington's disease. *Elife* 7, e38744. [PubMed: 30179155]

- Bannister CA, Holden SE, Jenkins-Jones S, Morgan CL, Halcox JP, Scherthaner G, Mukherjee J, Currie CJ, 2014 Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls. *Diabetes Obes Metab* 16, 1165–1173. [PubMed: 25041462]
- Barini E, Antico O, Zhao Y, Asta F, Tucci V, Catelani T, Marotta R, Xu H, Gasparini L, 2016 Metformin promotes tau aggregation and exacerbates abnormal behavior in a mouse model of tauopathy. *Mol Neurodegener* 11, 16–16. [PubMed: 26858121]
- Barzilai N, Crandall JP, Kritchevsky SB, Espeland MA, 2016 Metformin as a Tool to Target Aging. *Cell metabolism* 23, 1060–1065. [PubMed: 27304507]
- Bass TM, Weinkove D, Houthoofd K, Gems D, Partridge L, 2007 Effects of resveratrol on lifespan in *Drosophila melanogaster* and *Caenorhabditis elegans*. *Mechanisms of ageing and development* 128, 546–552. [PubMed: 17875315]
- Bastianetto S, Ménard C, Quirion R, 2015 Neuroprotective action of resveratrol. *Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease* 1852, 1195–1201. [PubMed: 25281824]
- Bauer JH, Goupil S, Garber GB, Helfand SL, 2004 An accelerated assay for the identification of lifespan-extending interventions in *Drosophila melanogaster*. *Proceedings of the National Academy of Sciences of the United States of America* 101, 12980–12985. [PubMed: 15328413]
- Baum L, Lam C, Cheung S, Kwok T, Lui V, Tsoh J, Lam L, Leung V, Hui E, Ng C, Woo J, Chiu H, Goggins W, Zee B, Cheng K, Fong C, Wong A, Mok H, Chow M, Ho P, Ip S, Ho C, Yu X, Lai C, Chan M, Szeto S, Chan I, Mok V, 2008 Six-Month Randomized, Placebo-Controlled, Double-Blind, Pilot Clinical Trial of Curcumin in Patients With Alzheimer Disease. *Journal of Clinical Psychopharmacology* 1.
- Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, Prabhu VV, Allard JS, Lopez-Lluch G, Lewis K, Pistell PJ, Poosala S, Becker KG, Boss O, Gwinn D, Wang M, Ramaswamy S, Fishbein KW, Spencer RG, Lakatta EG, Le Couteur D, Shaw RJ, Navas P, Puigserver P, Ingram DK, de Cabo R, Sinclair DA, 2006 Resveratrol improves health and survival of mice on a high-calorie diet. *Nature* 444, 337–342. [PubMed: 17086191]
- Bavarsad Shahripour R, Harrigan MR, Alexandrov AV, 2014 N-acetylcysteine (NAC) in neurological disorders: mechanisms of action and therapeutic opportunities. *Brain and Behavior* 4, 108–122. [PubMed: 24683506]
- Bayliss JA, Lemus MB, Santos VV, Deo M, Davies JS, Kemp BE, Elsworth JD, Andrews ZB, 2016 Metformin Prevents Nigrostriatal Dopamine Degeneration Independent of AMPK Activation in Dopamine Neurons. *PloS one* 11, e0159381–e0159381. [PubMed: 27467571]
- Begum AN, Jones MR, Lim GP, Morihara T, Kim P, Heath DD, Rock CL, Pruitt MA, Yang F, Hudspeth B, Hu S, Faull KF, Teter B, Cole GM, Frautschy SA, 2008 Curcumin structure-function, bioavailability, and efficacy in models of neuroinflammation and Alzheimer's disease. *J Pharmacol Exp Ther* 326, 196–208. [PubMed: 18417733]
- Behr D, Wu J, Cumine S, Kim KW, Lu SC, Atangan L, Wang M, 2009 Resveratrol is not a direct activator of SIRT1 enzyme activity. *Chemical biology & drug design* 74, 619–624. [PubMed: 19843076]
- Bence NF, Sampat RM, Kopito RR, 2001 Impairment of the ubiquitin-proteasome system by protein aggregation. *Science* 292, 1552–1555. [PubMed: 11375494]
- Beretta S, Sala G, Mattavelli L, Ceresa C, Casciati A, Ferri A, Carrì MT, Ferrarese C, 2003 Mitochondrial dysfunction due to mutant copper/zinc superoxide dismutase associated with amyotrophic lateral sclerosis is reversed by N-acetylcysteine. *Neurobiology of disease* 13, 213–221. [PubMed: 12901835]
- Berger Z, Ravikumar B, Menzies FM, Oroz LG, Underwood BR, Pangalos MN, Schmitt I, Wullner U, Evert BO, O'Kane CJ, Rubinsztein DC, 2006 Rapamycin alleviates toxicity of different aggregate-prone proteins. *Hum Mol Genet* 15, 433–442. [PubMed: 16368705]
- Bjedov I, Toivonen JM, Kerr F, Slack C, Jacobson J, Foley A, Partridge L, 2010 Mechanisms of life span extension by rapamycin in the fruit fly *Drosophila melanogaster*. *Cell Metab* 11, 35–46. [PubMed: 20074526]

- Blanchet J, Longpré F, Bureau G, Morissette M, DiPaolo T, Bronchti G, Martinoli MG, 2008 Resveratrol, a red wine polyphenol, protects dopaminergic neurons in MPTP-treated mice. *Progress in neuro-psychopharmacology & biological psychiatry* 32, 1243–1250. [PubMed: 18471948]
- Bocitto M, Lamitina T, Kalb RG, 2012 Daf-2 signaling modifies mutant SOD1 toxicity in *C. elegans*. *PLoS one* 7, e33494. [PubMed: 22457769]
- Bohlken J, Jacob L, Kostev K, 2018 Association Between the Use of Antihyperglycemic Drugs and Dementia Risk: A Case-Control Study. *J Alzheimers Dis* 66, 725–732. [PubMed: 30320593]
- Bond L, Bowen G, Mertens B, Denson K, Jordan K, Vidakovic B, Mitchell SC, 2020 Associations of Patient Mood, Modulators of Quality of Life, and Pharmaceuticals with Amyotrophic Lateral Sclerosis Survival Duration. *Behavioral Sciences* 10.
- Bove J, Martinez-Vicente M, Vila M, 2011 Fighting neurodegeneration with rapamycin: mechanistic insights. *Nat Rev Neurosci* 12, 437–452. [PubMed: 21772323]
- Brack C, Bechter-Thüring E, Labuhn M, 1997 N-Acetylcysteine slows down ageing and increases the life span of *Drosophila melanogaster*. *Cellular and Molecular Life Sciences CMLS* 53, 960–966. [PubMed: 9447249]
- Brignull HR, Moore FE, Tang SJ, Morimoto RI, 2006 Polyglutamine proteins at the pathogenic threshold display neuron-specific aggregation in a pan-neuronal *Caenorhabditis elegans* model. *J Neurosci* 26, 7597–7606. [PubMed: 16855087]
- Browne SE, Beal MF, 2006 Oxidative damage in Huntington's disease pathogenesis. *Antioxid Redox Signal* 8, 2061–2073. [PubMed: 17034350]
- Bump EA, Brown JM, 1990 Role of glutathione in the radiation response of mammalian cells invitro and in vivo. *Pharmacology & Therapeutics* 47, 117–136. [PubMed: 2195553]
- Byrne S, Walsh C, Lynch C, Bede P, Elamin M, Kenna K, McLaughlin R, Hardiman O, 2011 Rate of familial amyotrophic lateral sclerosis: a systematic review and meta-analysis. *J Neurol Neurosurg Psychiatry* 82, 623–627. [PubMed: 21047878]
- Cabreiro F, Au C, Leung K-Y, Vergara-Irigaray N, Cochemé HM, Noori T, Weinkove D, Schuster E, Greene NDE, Gems D, 2013 Metformin retards aging in *C. elegans* by altering microbial folate and methionine metabolism. *Cell* 153, 228–239. [PubMed: 23540700]
- Caccamo A, Majumder S, Deng JJ, Bai Y, Thornton FB, Oddo S, 2009 Rapamycin rescues TDP-43 mislocalization and the associated low molecular mass neurofilament instability. *J Biol Chem* 284, 27416–27424. [PubMed: 19651785]
- Caccamo A, Majumder S, Richardson A, Strong R, Oddo S, 2010 Molecular Interplay between Mammalian Target of Rapamycin (mTOR), Amyloid- β , and Tau. *Journal of Biological Chemistry* 285, 13107–13120. [PubMed: 20178983]
- Campbell JM, Bellman SM, Stephenson MD, Lisy K, 2017 Metformin reduces all-cause mortality and diseases of ageing independent of its effect on diabetes control: A systematic review and meta-analysis. *Ageing Research Reviews* 40, 31–44. [PubMed: 28802803]
- Capiralla H, Vingtdoux V, Zhao H, Sankowski R, Al-Abed Y, Davies P, Marambaud P, 2012 Resveratrol mitigates lipopolysaccharide- and A β -mediated microglial inflammation by inhibiting the TLR4/NF- κ B/STAT signaling cascade. *J Neurochem* 120, 461–472. [PubMed: 22118570]
- Chandrashekara KT, Popli S, Shakarad MN, 2014 Curcumin enhances parental reproductive lifespan and progeny viability in *Drosophila melanogaster*. *Age* 36.
- Chen B, Teng Y, Zhang X, Lv X, Yin Y, 2016 Metformin Alleviated A β -Induced Apoptosis via the Suppression of JNK MAPK Signaling Pathway in Cultured Hippocampal Neurons. *Biomed Res Int* 2016, 1421430–1421430. [PubMed: 27403417]
- Chen CY, Jang JH, Li MH, Surh YJ, 2005 Resveratrol upregulates heme oxygenase-1 expression via activation of NF-E2-related factor 2 in PC12 cells. *Biochemical and biophysical research communications* 331, 993–1000. [PubMed: 15882976]
- Chen J-L, Luo C, Pu D, Zhang G-Q, Zhao Y-X, Sun Y, Zhao K-X, Liao Z-Y, Lv A-K, Zhu S-Y, Zhou J, Xiao Q, 2019 Metformin attenuates diabetes-induced tau hyperphosphorylation in vitro and in vivo by enhancing autophagic clearance. *Experimental neurology* 311, 44–56. [PubMed: 30219731]

- Chen Y, Liu X, Jiang C, Liu L, Ordovas JM, Lai CQ, Shen L, 2018 Curcumin supplementation increases survival and lifespan in *Drosophila* under heat stress conditions. *Biofactors* 44, 577–587. [PubMed: 30488487]
- Chen Y, Shu W, Chen W, Wu Q, Liu H, Cui G, 2007 Curcumin, both histone deacetylase and p300/CBP-specific inhibitor, represses the activity of nuclear factor kappa B and Notch 1 in Raji cells. *Basic Clin Pharmacol Toxicol* 101, 427–433. [PubMed: 17927689]
- Chen Y, Zhou K, Wang R, Liu Y, Kwak Y-D, Ma T, Thompson RC, Zhao Y, Smith L, Gasparini L, Luo Z, Xu H, Liao F-F, 2009 Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcription. *Proceedings of the National Academy of Sciences of the United States of America* 106, 3907–3912. [PubMed: 19237574]
- Cheng C, Lin C-H, Tsai Y-W, Tsai C-J, Chou P-H, Lan T-H, 2014 Type 2 diabetes and antidiabetic medications in relation to dementia diagnosis. *The journals of gerontology. Series A, Biological sciences and medical sciences* 69, 1299–1305.
- Cheng CW, Lin MJ, Shen CK, 2015 Rapamycin alleviates pathogenesis of a new *Drosophila* model of ALS-TDP. *J Neurogenet* 29, 59–68. [PubMed: 26219309]
- Cheng KK, Yeung CF, Ho SW, Chow SF, Chow AH, Baum L, 2013 Highly stabilized curcumin nanoparticles tested in an in vitro blood-brain barrier model and in Alzheimer's disease Tg2576 mice. *AAPS J* 15, 324–336. [PubMed: 23229335]
- Chico L, Ienco EC, Bisordi C, Lo Gerfo A, Petrozzi L, Petrucci A, Mancuso M, Siciliano G, 2018 Amyotrophic Lateral Sclerosis and Oxidative Stress: A Double-Blind Therapeutic Trial After Curcumin Supplementation. *CNS Neurol Disord Drug Targets* 17, 767–779. [PubMed: 30033879]
- Chiò A, Logroscino G, Traynor BJ, Collins J, Simeone JC, Goldstein LA, White LA, 2013 Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. *Neuroepidemiology* 41, 118–130. [PubMed: 23860588]
- Chiu S, Terpstra KJ, Bureau Y, Hou J, Raheb H, Cernvosky Z, Badmeav V, Copen J, Husni M, Woodbury-Farina M, 2013 Liposomal-formulated curcumin [Lipocurc] targeting HDAC (histone deacetylase) prevents apoptosis and improves motor deficits in Park 7 (DJ-1)-knockout rat model of Parkinson's disease: implications for epigenetics-based nanotechnology-driven drug platform. *J Complement Integr Med* 10.
- Choi J, Chen J, Schreiber SL, Clardy J, 1996 Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP. *Science* 273, 239–242. [PubMed: 8662507]
- Chongtham A, Agrawal N, 2016 Curcumin modulates cell death and is protective in Huntington's disease model. *Scientific reports* 6, 18736. [PubMed: 26728250]
- Churchill M, Chadburn A, Bilinski RT, Bertagnolli MM, 2000 Inhibition of intestinal tumors by curcumin is associated with changes in the intestinal immune cell profile. *J Surg Res* 89, 169–175. [PubMed: 10729246]
- Clark J, Clore EL, Zheng K, Adame A, Masliah E, Simon DK, 2010 Oral N-acetyl-cysteine attenuates loss of dopaminergic terminals in alpha-synuclein overexpressing mice. *PloS one* 5, e12333–e12333. [PubMed: 20808797]
- Cohen E, Bieschke J, Perciavalle RM, Kelly JW, Dillin A, 2006 Opposing activities protect against age-onset proteotoxicity. *Science* 313, 1604–1610. [PubMed: 16902091]
- Cohen E, Paulsson JF, Blinder P, Burstyn-Cohen T, Du D, Estepa G, Adame A, Pham HM, Holzenberger M, Kelly JW, Masliah E, Dillin A, 2009 Reduced IGF-1 signaling delays age-associated proteotoxicity in mice. *Cell* 139, 1157–1169. [PubMed: 20005808]
- Collier TJ, Kanaan NM, Kordower JH, 2011 Ageing as a primary risk factor for Parkinson's disease: evidence from studies of non-human primates. *Nature reviews. Neuroscience* 12, 359–366. [PubMed: 21587290]
- Cook C, Petrucelli L, 2009 A critical evaluation of the ubiquitin-proteasome system in Parkinson's disease. *Biochim Biophys Acta* 1792, 664–675. [PubMed: 19419700]
- Cooper JF, Dues DJ, Spielbauer KK, Machiela E, Senchuk MM, Van Raamsdonk JM, 2015 Delaying aging is neuroprotective in Parkinson's disease: a genetic analysis in *C. elegans* models. *NPJ Parkinson's disease* 1, 15022.

- Costa M, Bernardi J, Fiuza T, Costa L, Brandao R, Pereira ME, 2016 N-acetylcysteine protects memory decline induced by streptozotocin in mice. *Chem Biol Interact* 253, 10–17. [PubMed: 27087133]
- Crews L, Spencer B, Desplats P, Patrick C, Paulino A, Rockenstein E, Hansen L, Adame A, Galasko D, Masliah E, 2010 Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-synucleinopathy. *PLoS One* 5, e9313. [PubMed: 20174468]
- Cristòfol R, Porquet D, Corpas R, Coto-Montes A, Serret J, Camins A, Pallàs M, Sanfeliu C, 2012 Neurons from senescence-accelerated SAMP8 mice are protected against frailty by the sirtuin 1 promoting agents melatonin and resveratrol. *Journal of pineal research* 52, 271–281. [PubMed: 22085194]
- Dai J, Gu L, Su Y, Wang Q, Zhao Y, Chen X, Deng H, Li W, Wang G, Li K, 2018 Inhibition of curcumin on influenza A virus infection and influenzal pneumonia via oxidative stress, TLR2/4, p38/JNK MAPK and NF-kappaB pathways. *Int Immunopharmacol* 54, 177–187. [PubMed: 29153953]
- Das S, Das DK, 2007 Anti-inflammatory responses of resveratrol. *Inflammation & allergy drug targets* 6, 168–173. [PubMed: 17897053]
- Dasgupta B, Milbrandt J, 2007 Resveratrol stimulates AMP kinase activity in neurons. *Proceedings of the National Academy of Sciences of the United States of America* 104, 7217–7222. [PubMed: 17438283]
- Deepmala Slattery, J., Kumar N, Delhey L, Berk M, Dean O, Spielholz C, Frye R, 2015 Clinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review. *Neuroscience & Biobehavioral Reviews* 55, 294–321.
- Dehay B, Bove J, Rodriguez-Muela N, Perier C, Recasens A, Boya P, Vila M, 2010 Pathogenic lysosomal depletion in Parkinson's disease. *J Neurosci* 30, 12535–12544. [PubMed: 20844148]
- Dekhuijzen PN, 2004 Antioxidant properties of N-acetylcysteine: their relevance in relation to chronic obstructive pulmonary disease. *Eur Respir J* 23, 629–636. [PubMed: 15083766]
- del Aguila MA, Longstreth WT Jr., McGuire V, Koepsell TD, van Belle G, 2003 Prognosis in amyotrophic lateral sclerosis: a population-based study. *Neurology* 60, 813–819. [PubMed: 12629239]
- Deng HX, Zhai H, Bigio EH, Yan J, Fecto F, Ajroud K, Mishra M, Ajroud-Driss S, Heller S, Sufit R, Siddique N, Mugnaini E, Siddique T, 2010 FUS-immunoreactive inclusions are a common feature in sporadic and non-SOD1 familial amyotrophic lateral sclerosis. *Ann Neurol* 67, 739–748. [PubMed: 20517935]
- DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, Vonsattel JP, Aronin N, 1997 Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. *Science* 277, 1990–1993. [PubMed: 9302293]
- Dong H, Xu L, Wu L, Wang X, Duan W, Li H, Li C, 2014 Curcumin abolishes mutant TDP-43 induced excitability in a motoneuron-like cellular model of ALS. *Neuroscience* 272, 141–153. [PubMed: 24785678]
- Driver JA, Logroscino G, Gaziano JM, Kurth T, 2009 Incidence and remaining lifetime risk of Parkinson disease in advanced age. *Neurology* 72, 432–438. [PubMed: 19188574]
- Du XX, Xu HM, Jiang H, Song N, Wang J, Xie JX, 2012 Curcumin protects nigral dopaminergic neurons by iron-chelation in the 6-hydroxydopamine rat model of Parkinson's disease. *Neurosci Bull* 28, 253–258. [PubMed: 22622825]
- Dulovic M, Jovanovic M, Xilouri M, Stefanis L, Harhaji-Trajkovic L, Kravic-Stevovic T, Paunovic V, Ardah MT, El-Agnaf OMA, Kostic V, Markovic I, Trajkovic V, 2014 The protective role of AMP-activated protein kinase in alpha-synuclein neurotoxicity in vitro. *Neurobiology of disease* 63, 1–11. [PubMed: 24269733]
- Elifani F, Amico E, Pepe G, Capocci L, Castaldo S, Rosa P, Montano E, Pollice A, Madonna M, Filosa S, Calogero A, Maglione V, Crispi S, Di Pardo A, 2019 Curcumin dietary supplementation ameliorates disease phenotype in an animal model of Huntington's disease. *Hum Mol Genet* 28, 4012–4021. [PubMed: 31630202]

- Ezerina D, Takano Y, Hanaoka K, Urano Y, Dick TP, 2018 N-Acetyl Cysteine Functions as a Fast-Acting Antioxidant by Triggering Intracellular H₂S and Sulfane Sulfur Production. *Cell Chem Biol* 25, 447–459.e444. [PubMed: 29429900]
- Faber PW, Alter JR, MacDonald ME, Hart AC, 1999 Polyglutamine-mediated dysfunction and apoptotic death of a *Caenorhabditis elegans* sensory neuron. *Proc Natl Acad Sci U S A* 96, 179–184. [PubMed: 9874792]
- Farr SA, Roesler E, Niehoff ML, Roby DA, McKee A, Morley JE, 2019 Metformin Improves Learning and Memory in the SAMP8 Mouse Model of Alzheimer's Disease. *J Alzheimers Dis* 68, 1699–1710. [PubMed: 30958364]
- Feng X, Liang N, Zhu D, Gao Q, Peng L, Dong H, Yue Q, Liu H, Bao L, Zhang J, Hao J, Gao Y, Yu X, Sun J, 2013 Resveratrol inhibits β -amyloid-induced neuronal apoptosis through regulation of SIRT1-ROCK1 signaling pathway. *PLoS one* 8, e59888. [PubMed: 23555824]
- Feng X, Pan J, Li J, Zeng C, Qi W, Shao Y, Liu X, Liu L, Xiao G, Zhang H, Bai X, Cai D, 2020 Metformin attenuates cartilage degeneration in an experimental osteoarthritis model by regulating AMPK/mTOR. *Aging* 12, 1087–1103. [PubMed: 31945013]
- Fernandez-Funez P, Nino-Rosales ML, de Gouyon B, She WC, Luchak JM, Martinez P, Turiegano E, Benito J, Capovilla M, Skinner PJ, McCall A, Canal I, Orr HT, Zoghbi HY, Botas J, 2000 Identification of genes that modify ataxin-1-induced neurodegeneration. *Nature* 408, 101–106. [PubMed: 11081516]
- Ferretta A, Gaballo A, Tanzarella P, Piccoli C, Capitanio N, Nico B, Annese T, Di Paola M, Dell'aquila C, De Mari M, Ferranini E, Bonifati V, Pacelli C, Cocco T, 2014 Effect of resveratrol on mitochondrial function: implications in parkin-associated familial Parkinson's disease. *Biochimica et biophysica acta* 1842, 902–915. [PubMed: 24582596]
- Flurkey K, Astle CM, Harrison DE, 2010 Life extension by diet restriction and N-acetyl-L-cysteine in genetically heterogeneous mice. *Journals of Gerontology Series A: Biomedical Sciences and Medical Sciences* 65, 1275–1284.
- Fok WC, Chen Y, Bokov A, Zhang Y, Salmon AB, Diaz V, Javors M, Wood WH 3rd, Zhang Y, Becker KG, Perez VI, Richardson A, 2014 Mice fed rapamycin have an increase in lifespan associated with major changes in the liver transcriptome. *PLoS One* 9, e83988. [PubMed: 24409289]
- Fox JH, Connor T, Chopra V, Dorsey K, Kama JA, Bleckmann D, Betschart C, Hoyer D, Frentzel S, Difiglia M, Paganetti P, Hersch SM, 2010 The mTOR kinase inhibitor Everolimus decreases S6 kinase phosphorylation but fails to reduce mutant huntingtin levels in brain and is not neuroprotective in the R6/2 mouse model of Huntington's disease. *Mol Neurodegener* 5, 26. [PubMed: 20569486]
- Frautschy SA, Hu W, Kim P, Miller S, Chu T, Harris-White ME, Cole GM, 2001 Phenolic anti-inflammatory antioxidant reversal of A β -induced cognitive deficits and neuropathology. *Neurobiology of Aging* 22, 993–1005. [PubMed: 11755008]
- Freude S, Schilbach K, Schubert M, 2009 The role of IGF-1 receptor and insulin receptor signaling for the pathogenesis of Alzheimer's disease: from model organisms to human disease. *Current Alzheimer research* 6, 213–223. [PubMed: 19519303]
- Friedman DB, Johnson TE, 1988 A mutation in the age-1 gene in *Caenorhabditis elegans* lengthens life and reduces hermaphrodite fertility. *Genetics* 118, 75–86. [PubMed: 8608934]
- Fullerton MD, Galic S, Marcinko K, Sikkema S, Pulnilkunnit T, Chen Z-P, O'Neill HM, Ford RJ, Palanivel R, O'Brien M, Hardie DG, Macaulay SL, Schertzer JD, Dyck JRB, van Denderen BJ, Kemp BE, Steinberg GR, 2013 Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin. *Nat Med* 19, 1649–1654. [PubMed: 24185692]
- Fulop T, Witkowski JM, Bourgade K, Khalil A, Zerif E, Larbi A, Hirokawa K, Pawelec G, Bocti C, Lacombe G, Dupuis G, Frost EH, 2018 Can an Infection Hypothesis Explain the Beta Amyloid Hypothesis of Alzheimer's Disease? *Front Aging Neurosci* 10, 224. [PubMed: 30087609]
- Gaballah HH, Zakaria SS, Elbatsh MM, Tahoon NM, 2016 Modulatory effects of resveratrol on endoplasmic reticulum stress-associated apoptosis and oxido-inflammatory markers in a rat model of rotenone-induced Parkinson's disease. *Chemico-biological interactions* 251, 10–16. [PubMed: 27016191]

- Gadad B, Subramanya P, Pullabhatla S, Shantharam I, Rao KS, 2012 Curcumin-glucoside, A Novel Synthetic Derivative of Curcumin, Inhibits α -Synuclein Oligomer Formation: Relevance to Parkinson's Disease. *Current Pharmaceutical Design* 18, 76–84. [PubMed: 22211690]
- Gagliardi S, Franco V, Sorrentino S, Zucca S, Pandini C, Rota P, Bernuzzi S, Costa A, Sinforiani E, Pansarasa O, Cashman JR, Cereda C, 2018 Curcumin and Novel Synthetic Analogs in Cell-Based Studies of Alzheimer's Disease. *Front Pharmacol* 9, 1404. [PubMed: 30559668]
- Gandini S, Puntoni M, Heckman-Stoddard BM, Dunn BK, Ford L, DeCensi A, Szabo E, 2014 Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders. *Cancer Prev Res (Phila)* 7, 867–885. [PubMed: 24985407]
- Ganley IG, Lam du H, Wang J, Ding X, Chen S, Jiang X, 2009 ULK1.ATG13.FIP200 complex mediates mTOR signaling and is essential for autophagy. *J Biol Chem* 284, 12297–12305. [PubMed: 19258318]
- Garcia-Alloza M, Borrelli LA, Rozkalne A, Hyman BT, Bacskaï BJ, 2007 Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model. *J Neurochem* 102, 1095–1104. [PubMed: 17472706]
- Giannarelli R, Aragona M, Coppelli A, Del Prato S, 2003 Reducing insulin resistance with metformin: the evidence today. *Diabetes & Metabolism* 29, 6S28–26S35. [PubMed: 14502098]
- Gong Q-H, Li F, Jin F, Shi J-S, 2010 Resveratrol Attenuates Neuroinflammation-mediated Cognitive Deficits in Rats. *Journal of Health Science* 56, 655–663.
- Gormsen LC, Sundelin EI, Jensen JB, Vendelbo MH, Jakobsen S, Munk OL, Hougaard Christensen MM, Brøsen K, Frøkiær J, Jessen N, 2016 In Vivo Imaging of Human ¹¹C-Metformin in Peripheral Organs: Dosimetry, Biodistribution, and Kinetic Analyses. *Journal of Nuclear Medicine* 57, 1920–1926. [PubMed: 27469359]
- Granzotto A, Zatta P, 2011 Resveratrol acts not through anti-aggregative pathways but mainly via its scavenging properties against $A\beta$ and $A\beta$ -metal complexes toxicity. *PloS one* 6, e21565. [PubMed: 21738712]
- Gray M, Shirasaki DI, Cepeda C, Andre VM, Wilburn B, Lu XH, Tao J, Yamazaki I, Li SH, Sun YE, Li XJ, Levine MS, Yang XW, 2008 Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. *J Neurosci* 28, 6182–6195. [PubMed: 18550760]
- Greer EL, Dowlatshahi D, Banko MR, Villen J, Hoang K, Blanchard D, Gygi SP, Brunet A, 2007 An AMPK-FOXO pathway mediates longevity induced by a novel method of dietary restriction in *C. elegans*. *Curr Biol* 17, 1646–1656. [PubMed: 17900900]
- Griffin RJ, Moloney A, Kelliher M, Johnston JA, Ravid R, Dockery P, O'Connor R, O'Neill C, 2005 Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer's disease pathology. *J Neurochem* 93, 105–117. [PubMed: 15773910]
- Gruber J, Tang SY, Halliwell B, 2007 Evidence for a trade-off between survival and fitness caused by resveratrol treatment of *Caenorhabditis elegans*. *Annals of the New York Academy of Sciences* 1100, 530–542. [PubMed: 17460219]
- Guerrero EN, Wang H, Mitra J, Hegde PM, Stowell SE, Liachko NF, Kraemer BC, Garruto RM, Rao KS, Hegde ML, 2016 TDP-43/FUS in motor neuron disease: Complexity and challenges. *Prog Neurobiol* 145-146, 78–97. [PubMed: 27693252]
- Gupta SC, Kismali G, Aggarwal BB, 2013 Curcumin, a component of turmeric: from farm to pharmacy. *Biofactors* 39, 2–13. [PubMed: 23339055]
- Hamaguchi T, Ono K, Murase A, Yamada M, 2009 Phenolic compounds prevent Alzheimer's pathology through different effects on the amyloid-beta aggregation pathway. *Am J Pathol* 175, 2557–2565. [PubMed: 19893028]
- Hansen M, Taubert S, Crawford D, Libina N, Lee SJ, Kenyon C, 2007 Lifespan extension by conditions that inhibit translation in *Caenorhabditis elegans*. *Aging Cell* 6, 95–110. [PubMed: 17266679]
- Hardie DG, Ross FA, Hawley SA, 2012 AMPK: a nutrient and energy sensor that maintains energy homeostasis. *Nat Rev Mol Cell Biol* 13, 251–262. [PubMed: 22436748]

- Harish G, Venkateshappa C, Mythri RB, Dubey SK, Mishra K, Singh N, Vali S, Bharath MM, 2010 Bioconjugates of curcumin display improved protection against glutathione depletion mediated oxidative stress in a dopaminergic neuronal cell line: Implications for Parkinson's disease. *Bioorg Med Chem* 18, 2631–2638. [PubMed: 20227282]
- Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K, Nadon NL, Wilkinson JE, Frenkel K, Carter CS, Pahor M, Javors MA, Fernandez E, Miller RA, 2009 Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. *Nature* 460, 392–395. [PubMed: 19587680]
- Henchcliffe C, Beal MF, 2008 Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. *Nat Clin Pract Neurol* 4, 600–609. [PubMed: 18978800]
- Hervás D, Fornés-Ferrer V, Gómez-Escribano AP, Sequedo MD, Peiró C, Millán JM, Vázquez-Manrique RP, 2017 Metformin intake associates with better cognitive function in patients with Huntington's disease. *PLoS one* 12, e0179283–e0179283. [PubMed: 28632780]
- Hewlings SJ, Kalman DS, 2017 Curcumin: A Review of Its' Effects on Human Health. *Foods* 6.
- Hickey MA, Zhu C, Medvedeva V, Lerner RP, Patassini S, Franich NR, Maiti P, Frautschy SA, Zeitlin S, Levine MS, Chesselet MF, 2012 Improvement of neuropathology and transcriptional deficits in CAG 140 knock-in mice supports a beneficial effect of dietary curcumin in Huntington's disease. *Mol Neurodegener* 7, 12. [PubMed: 22475209]
- Ho DJ, Calingasan NY, Wille E, Dumont M, Beal MF, 2010 Resveratrol protects against peripheral deficits in a mouse model of Huntington's disease. *Experimental neurology* 225, 74–84. [PubMed: 20561979]
- Holzenberger M, Dupont J, Ducos B, Leneuve P, Geloën A, Even PC, Cervera P, Le Bouc Y, 2003 IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice. *Nature* 421, 182–187. [PubMed: 12483226]
- Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG, Zipkin RE, Chung P, Kisielewski A, Zhang LL, Scherer B, Sinclair DA, 2003 Small molecule activators of sirtuins extend *Saccharomyces cerevisiae* lifespan. *Nature* 425, 191–196. [PubMed: 12939617]
- Hsiao YH, Chen PS, Yeh SH, Lin CH, Gean PW, 2008 N-acetylcysteine prevents β -amyloid toxicity by a stimulatory effect on p35/cyclin-dependent kinase 5 activity in cultured cortical neurons. *Journal of neuroscience research* 86, 2685–2695. [PubMed: 18512759]
- Hsu AL, Murphy CT, Kenyon C, 2003 Regulation of aging and age-related disease by DAF-16 and heat-shock factor. *Science* 300, 1142–1145. [PubMed: 12750521]
- Hsu C-C, Wahlqvist ML, Lee M-S, Tsai H-N, 2011 Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin. *J Alzheimers Dis* 24, 485–493. [PubMed: 21297276]
- Hu M, Ye P, Liao H, Chen M, Yang F, 2016 Metformin Protects H9C2 Cardiomyocytes from High-Glucose and Hypoxia/Reoxygenation Injury via Inhibition of Reactive Oxygen Species Generation and Inflammatory Responses: Role of AMPK and JNK. *J Diabetes Res* 2016, 2961954–2961954. [PubMed: 27294149]
- Huang Q, Aluise CD, Joshi G, Sultana R, St Clair DK, Markesbery WR, Butterfield DA, 2010 Potential in vivo amelioration by N-acetyl-L-cysteine of oxidative stress in brain in human double mutant APP/PS-1 knock-in mice: toward therapeutic modulation of mild cognitive impairment. *J Neurosci Res* 88, 2618–2629. [PubMed: 20648652]
- Huang T-C, Lu K-T, Wo Y-YP, Wu Y-J, Yang Y-L, 2011 Resveratrol protects rats from A β -induced neurotoxicity by the reduction of iNOS expression and lipid peroxidation. *PLoS one* 6, e29102–e29102. [PubMed: 22220203]
- Imfeld P, Bodmer M, Jick SS, Meier CR, 2012 Metformin, other antidiabetic drugs, and risk of Alzheimer's disease: a population-based case-control study. *J Am Geriatr Soc* 60, 916–921. [PubMed: 22458300]
- Jang M, Pezzuto JM, 1999 Cancer chemopreventive activity of resveratrol. *Drugs under experimental and clinical research* 25, 65–77. [PubMed: 10370867]
- Jiang M, Wang J, Fu J, Du L, Jeong H, West T, Xiang L, Peng Q, Hou Z, Cai H, Seredenina T, Arbez N, Zhu S, Sommers K, Qian J, Zhang J, Mori S, Yang XW, Tamashiro KL, Aja S, Moran TH, Luthi-Carter R, Martin B, Maudsley S, Mattson MP, Cichewicz RH, Ross CA, Holtzman DM,

- Krainc D, Duan W, 2012 Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets. *Nature medicine* 18, 153–158.
- Jiang TF, Zhang YJ, Zhou HY, Wang HM, Tian LP, Liu J, Ding JQ, Chen SD, 2013 Curcumin ameliorates the neurodegenerative pathology in A53T alpha-synuclein cell model of Parkinson's disease through the downregulation of mTOR/p70S6K signaling and the recovery of macroautophagy. *J Neuroimmune Pharmacol* 8, 356–369. [PubMed: 23325107]
- Jin CY, Lee JD, Park C, Choi YH, Kim GY, 2007 Curcumin attenuates the release of pro-inflammatory cytokines in lipopolysaccharide-stimulated BV2 microglia. *Acta Pharmacol Sin* 28, 1645–1651. [PubMed: 17883952]
- Jin F, Wu Q, Lu YF, Gong QH, Shi JS, 2008 Neuroprotective effect of resveratrol on 6-OHDA-induced Parkinson's disease in rats. *European journal of pharmacology* 600, 78–82. [PubMed: 18940189]
- Jin J, Gu H, Anders NM, Ren T, Jiang M, Tao M, Peng Q, Rudek MA, Duan W, 2016 Metformin Protects Cells from Mutant Huntingtin Toxicity Through Activation of AMPK and Modulation of Mitochondrial Dynamics. *Neuromolecular Med* 18, 581–592. [PubMed: 27225841]
- Johnson S, Rabinovitch P, Kaeblerlein M, 2013 mTOR is a key modulator of ageing and age-related disease. *Nature* 493, 338–345. [PubMed: 23325216]
- Kaeblerlein M, McDonagh T, Heltweg B, Hixon J, Westman EA, Caldwell SD, Napper A, Curtis R, DiStefano PS, Fields S, Bedalov A, Kennedy BK, 2005 Substrate-specific activation of sirtuins by resveratrol. *The Journal of biological chemistry* 280, 17038–17045. [PubMed: 15684413]
- Kalender A, Selvaraj A, Kim SY, Gulati P, Brûlé S, Viollet B, Kemp BE, Bardeesy N, Dennis P, Schlager JJ, Marette A, Kozma SC, Thomas G, 2010 Metformin, Independent of AMPK, Inhibits mTORC1 in a Rag GTPase-Dependent Manner. *Cell Metabolism* 11, 390–401. [PubMed: 20444419]
- Kaneb HM, Sharp PS, Rahmani-Kondori N, Wells DJ, 2011 Metformin treatment has no beneficial effect in a dose-response survival study in the SOD1(G93A) mouse model of ALS and is harmful in female mice. *PloS one* 6, e24189–e24189. [PubMed: 21909419]
- Kang H, Khang R, Ham S, Jeong GR, Kim H, Jo M, Lee BD, Lee YI, Jo A, Park C, Kim H, Seo J, Paek SH, Lee Y-S, Choi J-Y, Lee Y, Shin J-H, 2017 Activation of the ATF2/CREB-PGC-1 α pathway by metformin leads to dopaminergic neuroprotection. *Oncotarget* 8, 48603–48618. [PubMed: 28611284]
- Kapahi P, Chen D, Rogers AN, Katewa SD, Li PW, Thomas EL, Kockel L, 2010 With TOR, less is more: a key role for the conserved nutrient-sensing TOR pathway in aging. *Cell Metab* 11, 453–465. [PubMed: 20519118]
- Kapahi P, Zid BM, Harper T, Koslover D, Sapin V, Benzer S, 2004 Regulation of lifespan in *Drosophila* by modulation of genes in the TOR signaling pathway. *Curr Biol* 14, 885–890. [PubMed: 15186745]
- Karuppagounder SS, Pinto JT, Xu H, Chen HL, Beal MF, Gibson GE, 2009 Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer's disease. *Neurochemistry international* 54, 111–118. [PubMed: 19041676]
- Kennedy BK, Berger SL, Brunet A, Campisi J, Cuervo AM, Epel ES, Franceschi C, Lithgow GJ, Morimoto RI, Pessin JE, Rando TA, Richardson A, Schadt EE, Wyss-Coray T, Sierra F, 2014 Geroscience: linking aging to chronic disease. *Cell* 159, 709–713. [PubMed: 25417146]
- Kenyon C, Chang J, Gensch E, Rudner A, Tabtiang R, 1993 A *C. elegans* mutant that lives twice as long as wild type. *Nature* 366, 461–464. [PubMed: 8247153]
- Khan MM, Ahmad A, Ishrat T, Khan MB, Hoda MN, Khuwaja G, Raza SS, Khan A, Javed H, Vaibhav K, Islam F, 2010 Resveratrol attenuates 6-hydroxydopamine-induced oxidative damage and dopamine depletion in rat model of Parkinson's disease. *Brain research* 1328, 139–151. [PubMed: 20167206]
- Khatri DK, Juvekar AR, 2016 Neuroprotective effect of curcumin as evinced by abrogation of rotenone-induced motor deficits, oxidative and mitochondrial dysfunctions in mouse model of Parkinson's disease. *Pharmacol Biochem Behav* 150-151, 39–47. [PubMed: 27619637]
- Khurana V, Lu Y, Steinhilb ML, Oldham S, Shulman JM, Feany MB, 2006 TOR-mediated cell-cycle activation causes neurodegeneration in a *Drosophila* tauopathy model. *Curr Biol* 16, 230–241. [PubMed: 16461276]

- Killick R, Scales G, Leroy K, Causevic M, Hooper C, Irvine EE, Choudhury AI, Drinkwater L, Kerr F, Al-Qassab H, Stephenson J, Yilmaz Z, Giese KP, Brion JP, Withers DJ, Lovestone S, 2009 Deletion of *Irs2* reduces amyloid deposition and rescues behavioural deficits in APP transgenic mice. *Biochemical and biophysical research communications* 386, 257–262. [PubMed: 19523444]
- Kim BK, Kim SA, Baek SM, Lee EY, Lee ES, Chung CH, Ahn CM, Park SK, 2019 Cur2004–8, a synthetic curcumin derivative, extends lifespan and modulates age-related physiological changes in *Caenorhabditis elegans*. *Drug Discov Ther* 13, 198–206. [PubMed: 31534071]
- Kim D, Nguyen MD, Dobbin MM, Fischer A, Sananbenesi F, Rodgers JT, Delalle I, Baur JA, Sui G, Armour SM, Puigserver P, Sinclair DA, Tsai LH, 2007 SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. *The EMBO journal* 26, 3169–3179. [PubMed: 17581637]
- Kim D, Park S, Kim J, 2001 Curcuminoids from *Curcuma longa* L. (Zingiberaceae) that protect PC12 rat pheochromocytoma and normal human umbilical vein endothelial cells from A β (1–42) insult. *Neuroscience Letters* 303, 57–61. [PubMed: 11297823]
- Kim HJ, Taylor JP, 2017 Lost in Transportation: Nucleocytoplasmic Transport Defects in ALS and Other Neurodegenerative Diseases. *Neuron* 96, 285–297. [PubMed: 29024655]
- Kim J, Kundu M, Viollet B, Guan KL, 2011 AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. *Nat Cell Biol* 13, 132–141. [PubMed: 21258367]
- King MA, Hands S, Hafiz F, Mizushima N, Tolkovsky AM, Wyttenbach A, 2008 Rapamycin inhibits polyglutamine aggregation independently of autophagy by reducing protein synthesis. *Mol Pharmacol* 73, 1052–1063. [PubMed: 18199701]
- Kitamura A, Kubota H, Pack CG, Matsumoto G, Hirayama S, Takahashi Y, Kimura H, Kinjo M, Morimoto RI, Nagata K, 2006 Cytosolic chaperonin prevents polyglutamine toxicity with altering the aggregation state. *Nat Cell Biol* 8, 1163–1170. [PubMed: 16980958]
- Kitani K, Osawa T, Yokozawa T, 2007 The effects of tetrahydrocurcumin and green tea polyphenol on the survival of male C57BL/6 mice. *Biogerontology* 8, 567–573. [PubMed: 17516143]
- Knight AL, Yan X, Hamamichi S, Ajjuri RR, Mazzulli JR, Zhang MW, Daigle JG, Zhang S, Borom AR, Roberts LR, Lee SK, DeLeon SM, Viollet-Djelassi C, Krainc D, O'Donnell JM, Caldwell KA, Caldwell GA, 2014 The glycolytic enzyme, GPI, is a functionally conserved modifier of dopaminergic neurodegeneration in Parkinson's models. *Cell metabolism* 20, 145–157. [PubMed: 24882066]
- Kong D, Yan Y, He XY, Yang H, Liang B, Wang J, He Y, Ding Y, Yu H, 2019 Effects of Resveratrol on the Mechanisms of Antioxidants and Estrogen in Alzheimer's Disease. *BioMed research international* 2019, 8983752. [PubMed: 31016201]
- Kuan Y-C, Huang K-W, Lin C-L, Hu C-J, Kao C-H, 2017 Effects of metformin exposure on neurodegenerative diseases in elderly patients with type 2 diabetes mellitus. *Prog Neuropsychopharmacol Biol Psychiatry* 79, 77–83. [PubMed: 28583443]
- Kulkarni AS, Brutsaert EF, Anghel V, Zhang K, Bloomgarden N, Pollak M, Mar JC, Hawkins M, Crandall JP, Barzilai N, 2018 Metformin regulates metabolic and nonmetabolic pathways in skeletal muscle and subcutaneous adipose tissues of older adults. *Aging Cell* 17.
- Labuzek K, Suchy D, Gabryel B, Bielecka A, Liber S, Okopien B, 2010 Quantification of metformin by the HPLC method in brain regions, cerebrospinal fluid and plasma of rats treated with lipopolysaccharide. *Pharmacol Rep* 62, 956–965. [PubMed: 21098880]
- Lambert M, Barlow A, Chromy B, Edwards C, Freed R, Liosatos M, Morgan T, Rozovsky I, Trommer S, Viola K, Wals P, Zhang C, Finch C, Krafft G, Klein W, 1998 Diffusible, nonfibrillar ligands derived from A β 1–42 are potent central nervous system neurotoxins. *Proc Natl Acad Sci U S A* 95, 6448–6453. [PubMed: 9600986]
- Lamming DW, Ye L, Sabatini DM, Baur JA, 2013 Rapalogs and mTOR inhibitors as anti-aging therapeutics. *J Clin Invest* 123, 980–989. [PubMed: 23454761]
- Laplante M, Sabatini DM, 2009 mTOR signaling at a glance. *J Cell Sci* 122, 3589–3594. [PubMed: 19812304]
- Laplante M, Sabatini DM, 2012 mTOR signaling in growth control and disease. *Cell* 149, 274–293. [PubMed: 22500797]

- Lee KS, Lee BS, Semnani S, Avanesian A, Um CY, Jeon HJ, Seong KM, Yu K, Min KJ, Jafari M, 2010 Curcumin extends life span, improves health span, and modulates the expression of age-associated aging genes in *Drosophila melanogaster*. *Rejuvenation Res* 13, 561–570. [PubMed: 20645870]
- Lehéricy S, Baulac M, Chiras J, Piérot L, Martin N, Pillon B, Deweer B, Dubois B, Marsault C, 1994 Amygdalohippocampal MR Volume Measurements in the Early Stages of Alzheimer Disease. *AJNR Am J Neuroradiol.* 5, 929–937.
- Lesne S, Koh MT, Kotilinek L, Kaye R, Glabe CG, Yang A, Gallagher M, Ashe KH, 2006 A specific amyloid-beta protein assembly in the brain impairs memory. *Nature* 440, 352–357. [PubMed: 16541076]
- Li J, Feng L, Xing Y, Wang Y, Du L, Xu C, Cao J, Wang Q, Fan S, Liu Q, Fan F, 2014a Radioprotective and antioxidant effect of resveratrol in hippocampus by activating Sirt1. *International journal of molecular sciences* 15, 5928–5939. [PubMed: 24722566]
- Li J, Kim SG, Blenis J, 2014b Rapamycin: one drug, many effects. *Cell Metab* 19, 373–379. [PubMed: 24508508]
- Li X, Valencia A, Sapp E, Masso N, Alexander J, Reeves P, Kegel KB, Aronin N, DiFiglia M, 2010 Aberrant Rab11-Dependent Trafficking of the Neuronal Glutamate Transporter EAAC1 Causes Oxidative Stress and Cell Death in Huntington's Disease. *The Journal of Neuroscience* 30, 4552. [PubMed: 20357106]
- Li XA, W-L; Alafuzzoff I; Soininen H; Winblad B; Pei J-J, 2004 Phosphorylated eukaryotic translation factor 4E is elevated in Alzheimer brain. *NeuroReport* 15, 2237–2240. [PubMed: 15371741]
- Liao VH, Yu CW, Chu YJ, Li WH, Hsieh YC, Wang TT, 2011 Curcumin-mediated lifespan extension in *Caenorhabditis elegans*. *Mech Ageing Dev* 132, 480–487. [PubMed: 21855561]
- Lim G, Chu T, Yang F, Beech W, Frautschy SA, Cole GM, 2001 The Curry Spice Curcumin Reduces Oxidative Damage and Amyloid Pathology in an Alzheimer Transgenic Mouse. *The Journal of Neuroscience* 21, 8370–8377. [PubMed: 11606625]
- Lin YT, Wu YC, Sun GC, Ho CY, Wong TY, Lin CH, Chen HH, Yeh TC, Li CJ, Tseng CJ, Cheng PW, 2018 Effect of Resveratrol on Reactive Oxygen Species-Induced Cognitive Impairment in Rats with Angiotensin II-Induced Early Alzheimer's Disease (dagger). *Journal of clinical medicine* 7.
- Liu HL, Chen Y, Cui GH, Zhou JF, 2005 Curcumin, a potent anti-tumor reagent, is a novel histone deacetylase inhibitor regulating B-NHL cell line Raji proliferation. *Acta Pharmacol Sin* 26, 603–609. [PubMed: 15842781]
- Liu Q, Zhu D, Jiang P, Tang X, Lang Q, Yu Q, Zhang S, Che Y, Feng X, 2019 Resveratrol synergizes with low doses of L-DOPA to improve MPTP-induced Parkinson disease in mice. *Behavioural brain research* 367, 10–18. [PubMed: 30922940]
- Liu Z, Xie Z, Jones W, Pavlovicz RE, Liu S, Yu J, Li PK, Lin J, Fuchs JR, Marcucci G, Li C, Chan KK, 2009 Curcumin is a potent DNA hypomethylation agent. *Bioorg Med Chem Lett* 19, 706–709. [PubMed: 19112019]
- Liu ZJ, Li ZH, Liu L, Tang WX, Wang Y, Dong MR, Xiao C, 2016 Curcumin Attenuates Beta-Amyloid-Induced Neuroinflammation via Activation of Peroxisome Proliferator-Activated Receptor-Gamma Function in a Rat Model of Alzheimer's Disease. *Front Pharmacol* 7, 261. [PubMed: 27594837]
- Lofrumento DD, Nicolardi G, Cianciulli A, De Nuccio F, La Pesa V, Carofiglio V, Dragone T, Calvello R, Panaro MA, 2014 Neuroprotective effects of resveratrol in an MPTP mouse model of Parkinson's-like disease: possible role of SOCS-1 in reducing pro-inflammatory responses. *Innate immunity* 20, 249–260. [PubMed: 23764428]
- Lu M, Su C, Qiao C, Bian Y, Ding J, Hu G, 2016 Metformin Prevents Dopaminergic Neuron Death in MPTP/P-Induced Mouse Model of Parkinson's Disease via Autophagy and Mitochondrial ROS Clearance. *Int J Neuropsychopharmacol* 19, pyw047. [PubMed: 27207919]
- Luo J, Nikolaev AY, Imai S. i., Chen D, Su F, Shiloh A, Guarente L, Gu W, 2001 Negative Control of p53 by Sir2 α . Promotes Cell Survival under Stress. *Cell* 107, 137–148. [PubMed: 11672522]
- Ma QL, Yang F, Rosario ER, Ubeda OJ, Beech W, Gant DJ, Chen PP, Hudspeth B, Chen C, Zhao Y, Vinters HV, Frautschy SA, Cole GM, 2009 Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling:

- suppression by omega-3 fatty acids and curcumin. *J Neurosci* 29, 9078–9089. [PubMed: 19605645]
- Maher P, Dargusch R, Bodai L, Gerard PE, Purcell JM, Marsh JL, 2011 ERK activation by the polyphenols fisetin and resveratrol provides neuroprotection in multiple models of Huntington's disease. *Human molecular genetics* 20, 261–270. [PubMed: 20952447]
- Majumder S, Richardson A, Strong R, Oddo S, 2011 Inducing autophagy by rapamycin before, but not after, the formation of plaques and tangles ameliorates cognitive deficits. *PLoS One* 6, e25416. [PubMed: 21980451]
- Malagelada C, Jin ZH, Jackson-Lewis V, Przedborski S, Greene LA, 2010 Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson's disease. *J Neurosci* 30, 1166–1175. [PubMed: 20089925]
- Mancuso R, del Valle J, Modol L, Martinez A, Granado-Serrano AB, Ramirez-Nunez O, Pallas M, Portero-Otin M, Osta R, Navarro X, 2014 Resveratrol improves motoneuron function and extends survival in SOD1(G93A) ALS mice. *Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics* 11, 419–432. [PubMed: 24414863]
- Mandrioli J, D'Amico R, Zucchi E, Gessani A, Fini N, Fasano A, Caponnetto C, Chio A, Dalla Bella E, Lunetta C, Mazzini L, Marinou K, Soraru G, de Biasi S, Lo Tartaro D, Pinti M, Cossarizza A, group R.-A.i., 2018 Rapamycin treatment for amyotrophic lateral sclerosis: Protocol for a phase II randomized, double-blind, placebo-controlled, multicenter, clinical trial (RAP-ALS trial). *Medicine (Baltimore)* 97, e11119. [PubMed: 29901635]
- Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, Lawton M, Trotter Y, Lehrach H, Davies SW, Bates GP, 1996 Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. *Cell* 87, 493–506. [PubMed: 8898202]
- Manna SK, Mukhopadhyay A, Aggarwal BB, 2000 Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-kappa B, activator protein-1, and apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation. *Journal of immunology (Baltimore, Md. : 1950)* 164, 6509–6519.
- Mannick JB, Del Giudice G, Lattanzi M, Valiante NM, Praestgaard J, Huang B, Lonetto MA, Maecker HT, Kovarik J, Carson S, Glass DJ, Klickstein LB, 2014 mTOR inhibition improves immune function in the elderly. *Sci Transl Med* 6, 268ra179.
- Mannick JBM,M; Hockey HP; Roma G; Beibel M; Kulmatycki K; Watkins M; Shavlakadze T; Zhou W; Quinn D; Glass D; Klickstein, 2018 TORC1 Inhibition Enhances Immune Function and Reduces Infections in the Elderly. *Sci Transl Med* 10.
- Marambaud P, Zhao H, Davies P, 2005 Resveratrol promotes clearance of Alzheimer's disease amyloid-beta peptides. *The Journal of biological chemistry* 280, 37377–37382. [PubMed: 16162502]
- Marsh JL, Walker H, Theisen H, Zhu YZ, Fielder T, Purcell J, Thompson LM, 2000 Expanded polyglutamine peptides alone are intrinsically cytotoxic and cause neurodegeneration in *Drosophila*. *Hum Mol Genet* 9, 13–25. [PubMed: 10587574]
- Martin-Montalvo A, Mercken EM, Mitchell SJ, Palacios HH, Mote PL, Scheibye-Knudsen M, Gomes AP, Ward TM, Minor RK, Blouin M-J, Schwab M, Pollak M, Zhang Y, Yu Y, Becker KG, Bohr VA, Ingram DK, Sinclair DA, Wolf NS, Spindler SR, Bernier M, de Cabo R, 2013 Metformin improves healthspan and lifespan in mice. *Nat Commun* 4, 2192–2192. [PubMed: 23900241]
- Masini D, Bonito-Oliva A, Bertho M, Fisone G, 2018 Inhibition of mTORC1 Signaling Reverts Cognitive and Affective Deficits in a Mouse Model of Parkinson's Disease. *Front Neurol* 9, 208. [PubMed: 29686643]
- Matthes F, Hettich MM, Schilling J, Flores-Dominguez D, Blank N, Wiglenda T, Buntru A, Wolf H, Weber S, Vorberg I, Dagane A, Dittmar G, Wanker E, Ehninger D, Krauss S, 2018 Inhibition of the MID1 protein complex: a novel approach targeting APP protein synthesis. *Cell Death Discov* 4, 4–4.
- Maugeri A, Mazzone MG, Giuliano F, Vinciguerra M, Basile G, Barchitta M, Agodi A, 2018 Curcumin Modulates DNA Methyltransferase Functions in a Cellular Model of Diabetic Retinopathy. *Oxid Med Cell Longev* 2018, 5407482. [PubMed: 30057682]

- McLean C, Cherny R, Fraser F, Fuller S, Smith M, Beyreuther K, Bush A, Masters C, 1999 Soluble Pool of A β Amyloid as a Determinant of Severity of Neurodegeneration in Alzheimer's Disease. *Annals of Neurology* 46, 860–866. [PubMed: 10589538]
- Miller RA, Harrison DE, Astle CM, Baur JA, Boyd AR, de Cabo R, Fernandez E, Flurkey K, Javors MA, Nelson JF, Orihuela CJ, Pletcher S, Sharp ZD, Sinclair D, Starnes JW, Wilkinson JE, Nadon NL, Strong R, 2011 Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. *J Gerontol A Biol Sci Med Sci* 66, 191–201. [PubMed: 20974732]
- Monti DA, Zabrecky G, Kremens D, Liang TW, Wintering NA, Cai J, Wei X, Bazzan AJ, Zhong L, Bowen B, Intenzo CM, Iacovitti L, Newberg AB, 2016 N-Acetyl Cysteine May Support Dopamine Neurons in Parkinson's Disease: Preliminary Clinical and Cell Line Data. *PLoS One* 11, e0157602. [PubMed: 27309537]
- Morley JF, Brignull HR, Weyers JJ, Morimoto RI, 2002 The threshold for polyglutamine-expansion protein aggregation and cellular toxicity is dynamic and influenced by aging in *Caenorhabditis elegans*. *Proc Natl Acad Sci U S A* 99, 10417–10422. [PubMed: 12122205]
- Moussa C, Hebron M, Huang X, Ahn J, Rissman RA, Aisen PS, Turner RS, 2017 Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer's disease. *Journal of neuroinflammation* 14, 1. [PubMed: 28086917]
- Naia L, Rosenstock TR, Oliveira AM, Oliveira-Sousa SI, Caldeira GL, Carmo C, Laco MN, Hayden MR, Oliveira CR, Rego AC, 2017 Comparative Mitochondrial-Based Protective Effects of Resveratrol and Nicotinamide in Huntington's Disease Models. *Molecular neurobiology* 54, 5385–5399. [PubMed: 27590140]
- Nassar SZ, Badae NM, Issa YA, 2018 Effect of amylin on memory and central insulin resistance in a rat model of Alzheimer's disease. *Arch Physiol Biochem*, 1–9.
- Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM, McCluskey LF, Miller BL, Masliah E, Mackenzie IR, Feldman H, Feiden W, Kretschmar HA, Trojanowski JQ, Lee VMY, 2006 Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis. *Science* 314, 130. [PubMed: 17023659]
- Ng C-H, Guan MSH, Koh C, Ouyang X, Yu F, Tan E-K, O'Neill SP, Zhang X, Chung J, Lim K-L, 2012 AMP kinase activation mitigates dopaminergic dysfunction and mitochondrial abnormalities in *Drosophila* models of Parkinson's disease. *J Neurosci* 32, 14311–14317. [PubMed: 23055502]
- Ng TP, Feng L, Yap KB, Lee TS, Tan CH, Winblad B, 2014 Long-term metformin usage and cognitive function among older adults with diabetes. *J Alzheimers Dis* 41, 61–68. [PubMed: 24577463]
- Nguyen TT, Vuu MD, Huynh MA, Yamaguchi M, Tran LT, Dang TPT, 2018 Curcumin Effectively Rescued Parkinson's Disease-Like Phenotypes in a Novel *Drosophila melanogaster* Model with dUCH Knockdown. *Oxid Med Cell Longev* 2018, 2038267. [PubMed: 30057672]
- Niccoli T, Cabecinha M, Tillmann A, Kerr F, Wong CT, Cardenes D, Vincent AJ, Bettedi L, Li L, Grönke S, Dols J, Partridge L, 2016 Increased Glucose Transport into Neurons Rescues A β Toxicity in *Drosophila*. *Curr Biol* 26, 2291–2300. [PubMed: 27524482]
- Nichols E, Szoeki CEI, Vollset SE, Abbasi N, Abd-Allah F, Abdela J, Aichour MTE, Akinyemi RO, Alahdab F, Asgedom SW, Awasthi A, Barker-Collo SL, Baune BT, Béjot Y, Belachew AB, Bennett DA, Biadgo B, Bijani A, Bin Sayeed MS, Brayne C, Carpenter DO, Carvalho F, Catalá-López F, Cerin E, Choi J-YJ, Dang AK, Degefa MG, Djalalinia S, Dubey M, Duken EE, Edvardsson D, Endres M, Eskandarieh S, Faro A, Farzadfar F, Fereshtehnejad S-M, Fernandes E, Filip I, Fischer F, Gebre AK, Geremew D, Ghasemi-Kasman M, Gnedovskaya EV, Gupta R, Hachinski V, Hagos TB, Hamidi S, Hankey GJ, Haro JM, Hay SI, Irvani SSN, Jha RP, Jonas JB, Kalani R, Karch A, Kasaeian A, Khader YS, Khalil IA, Khan EA, Khanna T, Khoja TAM, Khubchandani J, Kisa A, Kissimova-Skarbek K, Kivimäki M, Koyanagi A, Krohn KJ, Logroscino G, Lorkowski S, Majdan M, Malekzadeh R, März W, Massano J, Mengistu G, Meretoja A, Mohammadi M, Mohammadi-Khanaposhtani M, Mokdad AH, Mondello S, Moradi G, Nagel G, Naghavi M, Naik G, Nguyen LH, Nguyen TH, Nirayo YL, Nixon MR, Ofori-Asenso R, Ogbo FA, Olagunju AT, Owolabi MO, Panda-Jonas S, Passos V.M.d.A., Pereira DM, Pinilla-Monsalve GD, Piradov MA, Pond CD, Poustchi H, Qorbani M, Radfar A, Reiner RC Jr.,

Robinson SR, Roshandel G, Rostami A, Russ TC, Sachdev PS, Safari H, Safiri S, Sahathevan R, Salimi Y, Satpathy M, Sawhney M, Saylan M, Sepanlou SG, Shafieesabet A, Shaikh MA, Sahraian MA, Shigematsu M, Shiri R, Shiue I, Silva JP, Smith M, Sobhani S, Stein DJ, Tabarés-Seisdedos R, Tovani-Palone MR, Tran BX, Tran TT, Tsegay AT, Ullah I, Venketasubramanian N, Vlassov V, Wang Y-P, Weiss J, Westerman R, Wijeratne T, Wyper GMA, Yano Y, Yimer EM, Yonemoto N, Yousefifard M, Zaidi Z, Zare Z, Vos T, Feigin VL, Murray CJL, 2019 Global, regional, and national burden of Alzheimer's disease and other dementias, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. *The Lancet Neurology* 18, 88–106. [PubMed: 30497964]

- Niraula P, Kim MS, 2019 N-Acetylcysteine extends lifespan of *Drosophila* via modulating ROS scavenger gene expression. *Biogerontology* 20, 533–543. [PubMed: 31115735]
- Oh S-I, Park J-K, Park S-K, 2015 Lifespan extension and increased resistance to environmental stressors by N-acetyl-L-cysteine in *Caenorhabditis elegans*. *Clinics* 70, 380–386. [PubMed: 26039957]
- Onken B, Driscoll M, 2010 Metformin induces a dietary restriction-like state and the oxidative stress response to extend *C. elegans* Healthspan via AMPK, LKB1, and SKN-1. *PLoS one* 5, e8758–e8758. [PubMed: 20090912]
- Ono K, Hasegawa K, Naiki H, Yamada M, 2004 Curcumin Has Potent Anti-Amyloidogenic Effects for Alzheimer's β -Amyloid Fibrils In Vitro. *Journal of Neuroscience Research* 75, 742–750. [PubMed: 14994335]
- Orkaby AR, Cho K, Cormack J, Gagnon DR, Driver JA, 2017 Metformin vs sulfonylurea use and risk of dementia in US veterans aged \geq 65 years with diabetes. *Neurology* 89, 1877–1885. [PubMed: 28954880]
- Ou Z, Kong X, Sun X, He X, Zhang L, Gong Z, Huang J, Xu B, Long D, Li J, Li Q, Xu L, Xuan A, 2018 Metformin treatment prevents amyloid plaque deposition and memory impairment in APP/PS1 mice. *Brain Behav Immun* 69, 351–363. [PubMed: 29253574]
- Pacholec M, Bleasdale JE, Chrunyk B, Cunningham D, Flynn D, Garofalo RS, Griffith D, Griffor M, Loulakis P, Pabst B, Qiu X, Stockman B, Thanabal V, Varghese A, Ward J, Withka J, Ahn K, 2010 SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. *The Journal of biological chemistry* 285, 8340–8351. [PubMed: 20061378]
- Paisan-Ruiz C, Jain S, Evans EW, Gilks WP, Simon J, van der Brug M, Lopez de Munain A, Aparicio S, Gil AM, Khan N, Johnson J, Martinez JR, Nicholl D, Carrera IM, Pena AS, de Silva R, Lees A, Marti-Masso JF, Perez-Tur J, Wood NW, Singleton AB, 2004 Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. *Neuron* 44, 595–600. [PubMed: 15541308]
- Pallos J, Bodai L, Lukacsovich T, Purcell JM, Steffan JS, Thompson LM, Marsh JL, 2008 Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a *Drosophila* model of Huntington's disease. *Human molecular genetics* 17, 3767–3775. [PubMed: 18762557]
- Pan J, Li H, Ma J, Tan Y, Xiao Q, Ding JQ, Chen SD, 2012 Curcumin inhibition of JNKs prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease through suppressing mitochondria dysfunction. *Translational Neurodegeneration* 1, 16. [PubMed: 23210631]
- Pan KZ, Palter JE, Rogers AN, Olsen A, Chen D, Lithgow GJ, Kapahi P, 2007 Inhibition of mRNA translation extends lifespan in *Caenorhabditis elegans*. *Aging Cell* 6, 111–119. [PubMed: 17266680]
- Pan T, Kondo S, Le W, Jankovic J, 2008 The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease. *Brain* 131, 1969–1978. [PubMed: 18187492]
- Panahi Y, Hosseini MS, Khalili N, Naimi E, Simental-Mendia LE, Majeed M, Sahebkar A, 2016 Effects of curcumin on serum cytokine concentrations in subjects with metabolic syndrome: A post-hoc analysis of a randomized controlled trial. *Biomed Pharmacother* 82, 578–582. [PubMed: 27470399]
- Pandareesh MD, Shrivash MK, Naveen Kumar HN, Misra K, Srinivas Bharath MM, 2016 Curcumin Monoglucoside Shows Improved Bioavailability and Mitigates Rotenone Induced Neurotoxicity in Cell and *Drosophila* Models of Parkinson's Disease. *Neurochem Res* 41, 3113–3128. [PubMed: 27535828]

- Panov AV, Gutekunst CA, Leavitt BR, Hayden MR, Burke JR, Strittmatter WJ, Greenamyre JT, 2002 Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. *Nat Neurosci* 5, 731–736. [PubMed: 12089530]
- Parker JA, Arango M, Abderrahmane S, Lambert E, Tourette C, Catoire H, Neri C, 2005 Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons. *Nature genetics* 37, 349–350. [PubMed: 15793589]
- Parker JA, Connolly JB, Wellington C, Hayden M, Dausset J, Neri C, 2001 Expanded polyglutamines in *Caenorhabditis elegans* cause axonal abnormalities and severe dysfunction of PLM mechanosensory neurons without cell death. *Proc Natl Acad Sci U S A* 98, 13318–13323. [PubMed: 11687635]
- Pearson KJ, Baur JA, Lewis KN, Peshkin L, Price NL, Labinskyy N, Swindell WR, Kamara D, Minor RK, Perez E, Jamieson HA, Zhang Y, Dunn SR, Sharma K, Pleshko N, Woollett LA, Csiszar A, Ikeno Y, Le Couteur D, Elliott PJ, Becker KG, Navas P, Ingram DK, Wolf NS, Ungvari Z, Sinclair DA, de Cabo R, 2008 Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. *Cell Metab* 8, 157–168. [PubMed: 18599363]
- Pei JJ, An WL, Zhou XW, Nishimura T, Norberg J, Benedikz E, Gotz J, Winblad B, 2006 P70 S6 kinase mediates tau phosphorylation and synthesis. *FEBS Lett* 580, 107–114. [PubMed: 16364302]
- Peters R, Ee N, Peters J, Booth A, Mudway I, Anstey KJ, 2019 Air Pollution and Dementia: A Systematic Review. *J Alzheimers Dis* 70, S145–S163. [PubMed: 30775976]
- Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL, 1997 Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. *Science* 276, 2045–2047. [PubMed: 9197268]
- Porquet D, Casadesús G, Bayod S, Vicente A, Canudas AM, Vilaplana J, Pelegrí C, Sanfeliu C, Camins A, Pallàs M, del Valle J, 2013 Dietary resveratrol prevents Alzheimer's markers and increases life span in SAMP8. *AGE* 35, 1851–1865. [PubMed: 23129026]
- Prakash A, Kalra JK, Kumar A, 2015 Neuroprotective effect of N-acetyl cysteine against streptozotocin-induced memory dysfunction and oxidative damage in rats. 26, 13.
- Prasad A, Bharathi V, Sivalingam V, Girdhar A, Patel BK, 2019 Molecular Mechanisms of TDP-43 Misfolding and Pathology in Amyotrophic Lateral Sclerosis. *Front Mol Neurosci* 12, 25. [PubMed: 30837838]
- Price Nathan L., Gomes Ana P., Ling Alvin J.Y., Duarte Filipe V., Martin-Montalvo A, North Brian J., Agarwal B, Ye L, Ramadori G, Teodoro Joao S., Hubbard Basil P., Varela Ana T., Davis James G., Varamini B, Hafner A, Moaddel R, Rolo Anabela P., Coppari R, Palmeira Carlos M., de Cabo R., Baur Joseph A., Sinclair David A., 2012 SIRT1 Is Required for AMPK Activation and the Beneficial Effects of Resveratrol on Mitochondrial Function. *Cell Metab* 15, 675–690. [PubMed: 22560220]
- Pryor WM, Biagioli M, Shahani N, Swarnkar S, Huang WC, Page DT, MacDonald ME, Subramaniam S, 2014 Huntingtin promotes mTORC1 signaling in the pathogenesis of Huntington's disease. *Sci Signal* 7, ra103. [PubMed: 25351248]
- Qian W, Li H, Pan N, Zhang C, 2018 Curcumin Treatment is Associated with Increased Expression of the N-Methyl-D-Aspartate Receptor (NMDAR) Subunit, NR2A, in a Rat PC12 Cell Line Model of Alzheimer's Disease Treated with the Acetyl Amyloid-beta Peptide, Abeta(25–35). *Med Sci Monit* 24, 2693–2699. [PubMed: 29714206]
- Qualls Z, Brown D, Ramlochan Singh C, Hurley LL, Tizabi Y, 2014 Protective effects of curcumin against rotenone and salsolinol-induced toxicity: implications for Parkinson's disease. *Neurotox Res* 25, 81–89. [PubMed: 24122264]
- Rahimmi A, Khosrobakhsh F, Izadpanah E, Moloudi MR, Hassanzadeh K, 2015 N-acetylcysteine prevents rotenone-induced Parkinson's disease in rat: An investigation into the interaction of parkin and Drp1 proteins. *Brain Research Bulletin* 113, 34–40. [PubMed: 25732239]

- Rascón B, Hubbard BP, Sinclair DA, Amdam GV, 2012 The lifespan extension effects of resveratrol are conserved in the honey bee and may be driven by a mechanism related to caloric restriction. *Aging (Albany NY)* 4, 499–508. [PubMed: 22868943]
- Ravikumar B, Vacher C, Berger Z, Davies JE, Luo S, Oroz LG, Scaravilli F, Easton DF, Duden R, O’Kane CJ, Rubinsztein DC, 2004 Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. *Nat Genet* 36, 585–595. [PubMed: 15146184]
- Ravikumar BD,R; Rubinsztein C, 2002 Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy. *Hum Mol Genet* 11, 1107–1117. [PubMed: 11978769]
- Regitz C, Fitzenberger E, Mahn FL, Dußling LM, Wenzel U, 2016 Resveratrol reduces amyloid-beta (A β 1–42)-induced paralysis through targeting proteostasis in an Alzheimer model of *Caenorhabditis elegans*. *European journal of nutrition* 55, 741–747. [PubMed: 25851110]
- Renaud S, de Lorgeril M, 1992 Wine, alcohol, platelets, and the French paradox for coronary heart disease. *Lancet (London, England)* 339, 1523–1526.
- Ringman JM, Frautschy SA, Teng E, Begum AN, Bardens J, Beigi M, Gyls KH, Badmaev V, Heath DD, Apostolova LG, Porter V, Vanek Z, Marshall GA, Helleman G, Sugar C, Masterman DL, Montine TJ, Cummings JL, Cole GM, 2012 Oral curcumin for Alzheimer’s disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study. *Alzheimers Res Ther* 4, 43. [PubMed: 23107780]
- Robida-Stubbs S, Glover-Cutter K, Lamming DW, Mizunuma M, Narasimhan SD, Neumann-Haefelin E, Sabatini DM, Blackwell TK, 2012 TOR signaling and rapamycin influence longevity by regulating SKN-1/Nrf and DAF-16/FoxO. *Cell metabolism* 15, 713–724. [PubMed: 22560223]
- Rodriguez M, Rodriguez-Sabate C, Morales I, Sanchez A, Sabate M, 2015 Parkinson’s disease as a result of aging. *Aging cell*.
- Sadagurski M, Cheng Z, Rozzo A, Palazzolo I, Kelley GR, Dong X, Krainc D, White MF, 2011 IRS2 increases mitochondrial dysfunction and oxidative stress in a mouse model of Huntington disease. *The Journal of clinical investigation* 121, 4070–4081. [PubMed: 21926467]
- Saewanee N, Praputpittaya T, Malaiwong N, Chalorak P, Meemon K, 2019 Neuroprotective effect of metformin on dopaminergic neurodegeneration and α -synuclein aggregation in *C. elegans* model of Parkinson’s disease. *Neuroscience Research*.
- Sanchis A, García-Gimeno MA, Cañada-Martínez AJ, Sequedo MD, Millán JM, Sanz P, Vázquez-Manrique RP, 2019 Metformin treatment reduces motor and neuropsychiatric phenotypes in the zQ175 mouse model of Huntington disease. *Exp Mol Med* 51, 65–65.
- Sandhir R, Sood A, Mehrotra A, Kamboj SS, 2012 N-Acetylcysteine Reverses Mitochondrial Dysfunctions and Behavioral Abnormalities in 3-Nitropropionic Acid-Induced Huntington’s Disease. *Neurodegenerative Diseases* 9, 145–157. [PubMed: 22327485]
- Sang Q, Liu X, Wang L, Qi L, Sun W, Wang W, Sun Y, Zhang H, 2018 Curcumin Protects an SH-SY5Y Cell Model of Parkinson’s Disease Against Toxic Injury by Regulating HSP90. *Cell Physiol Biochem* 51, 681–691. [PubMed: 30463061]
- Satyal SH, Schmidt E, Kitagawa K, Sondheimer N, Lindquist S, Kramer JM, Morimoto RI, 2000 Polyglutamine aggregates alter protein folding homeostasis in *Caenorhabditis elegans*. *Proc Natl Acad Sci U S A* 97, 5750–5755. [PubMed: 10811890]
- Scahill R, Schott J, Stevens J, Rossor M, Fox N, 2002 Mapping the evolution of regional atrophy in Alzheimer’s disease: Unbiased analysis of fluid-registered serial MRI. *Proc Natl Acad Sci U S A* 99, 4703–4707. [PubMed: 11930016]
- Schilling G, Becher MW, Sharp AH, Jinnah HA, Duan K, Kotzuk JA, Slunt HH, Ratovitski T, Cooper JK, Jenkins NA, Copeland NG, Price DL, Ross CA, Borchelt DR, 1999 Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. *Hum Mol Genet* 8, 397–407. [PubMed: 9949199]
- Schweiger S, Matthes F, Posey K, Kickstein E, Weber S, Hettich MM, Pfurtsceller S, Ehninger D, Schneider R, Krauß S, 2017 Resveratrol induces dephosphorylation of Tau by interfering with the MID1-PP2A complex. *Scientific reports* 7, 13753. [PubMed: 29062069]
- Selman C, Tullet JM, Wieser D, Irvine E, Lingard SJ, Choudhury AI, Claret M, Al-Qassab H, Carmignac D, Ramadani F, Woods A, Robinson IC, Schuster E, Batterham RL, Kozma SC,

- Thomas G, Carling D, Okkenhaug K, Thornton JM, Partridge L, Gems D, Withers DJ, 2009 Ribosomal protein S6 kinase 1 signaling regulates mammalian life span. *Science* 326, 140–144. [PubMed: 19797661]
- Seong KM, Yu M, Lee KS, Park S, Jin YW, Min KJ, 2015 Curcumin mitigates accelerated aging after irradiation in *Drosophila* by reducing oxidative stress. *Biomed Res Int* 2015, 425380. [PubMed: 25815315]
- Shahidi S, Zargooshnia S, Asl SS, Komaki A, Sarihi A, 2017 Influence of N-acetyl cysteine on beta-amyloid-induced Alzheimer's disease in a rat model: A behavioral and electrophysiological study. *Brain Res Bull* 131, 142–149. [PubMed: 28411131]
- Sharma M, Gupta YK, 2002 Chronic treatment with trans resveratrol prevents intracerebroventricular streptozotocin induced cognitive impairment and oxidative stress in rats. *Life sciences* 71, 2489–2498. [PubMed: 12270754]
- Sharma N, Nehru B, 2018 Curcumin affords neuroprotection and inhibits alpha-synuclein aggregation in lipopolysaccharide-induced Parkinson's disease model. *Inflammopharmacology* 26, 349–360. [PubMed: 29027056]
- Shen LR, Xiao F, Yuan P, Chen Y, Gao QK, Parnell LD, Meydani M, Ordovas JM, Li D, Lai CQ, 2013 Curcumin-supplemented diets increase superoxide dismutase activity and mean lifespan in *Drosophila*. *Age (Dordr)* 35, 1133–1142. [PubMed: 22653297]
- Shi Q, Liu S, Fonseca VA, Thethi TK, Shi L, 2019 Effect of metformin on neurodegenerative disease among elderly adult US veterans with type 2 diabetes mellitus. *BMJ Open* 9, e024954–e024954.
- Siddique YH, Naz F, Jyoti S, 2014 Effect of curcumin on lifespan, activity pattern, oxidative stress, and apoptosis in the brains of transgenic *Drosophila* model of Parkinson's disease. *Biomed Res Int* 2014, 606928. [PubMed: 24860828]
- Singh S, Aggarwal B, 1995 Activation of Transcription Factor NF- κ B Is Suppressed by Curcumin (Diferulolylmethane). *The Journal of Biological Chemistry* 270, 24995–25000. [PubMed: 7559628]
- Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, Lincoln S, Crawley A, Hanson M, Maraganore D, Adler C, Cookson MR, Muentner M, Baptista M, Miller D, Blancato J, Hardy J, Gwinn-Hardy K, 2003 alpha-Synuclein locus triplication causes Parkinson's disease. *Science* 302, 841. [PubMed: 14593171]
- Slack C, Foley A, Partridge L, 2012 Activation of AMPK by the putative dietary restriction mimetic metformin is insufficient to extend lifespan in *Drosophila*. *PLoS one* 7, e47699–e47699. [PubMed: 23077661]
- Slow EJ, van Raamsdonk J, Rogers D, Coleman SH, Graham RK, Deng Y, Oh R, Bissada N, Hossain SM, Yang YZ, Li XJ, Simpson EM, Gutekunst CA, Leavitt BR, Hayden MR, 2003 Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. *Hum Mol Genet* 12, 1555–1567. [PubMed: 12812983]
- Soh JW, Marowsky N, Nichols TJ, Rahman AM, Miah T, Sarao P, Khasawneh R, Unnikrishnan A, Heydari AR, Silver RB, Arking R, 2013 Curcumin is an early-acting stage-specific inducer of extended functional longevity in *Drosophila*. *Exp Gerontol* 48, 229–239. [PubMed: 23063786]
- Spilman P, Podlutska N, Hart MJ, Debnath J, Gorostiza O, Bredesen D, Richardson A, Strong R, Galvan V, 2010 Inhibition of mTOR by Rapamycin Abolishes Cognitive Deficits and Reduces Amyloid- β Levels in a Mouse Model of Alzheimer's Disease. *PLOS ONE* 5, e9979. [PubMed: 20376313]
- Staats KAH,S; Schonefeldt S; Bento-Abreu A; Dooley J; Van Damme, P.; Liston A; Robberecht W; Van Den Bosch, L., 2013 Rapamycin increases survival in ALS mice lacking mature lymphocytes. *Mol Neurodegener* 8.
- Stack EC, Matson WR, Ferrante RJ, 2008 Evidence of oxidant damage in Huntington's disease: translational strategies using antioxidants. *Annals of the New York Academy of Sciences* 1147, 79–92. [PubMed: 19076433]
- Stan RM,MM; Cafferkey R; Johnson RK; Rosenberg M; Livi GP, 1994 Interaction between FKBP12-Rapamycin and TOR Involves a Conserved Serine Residue. *The Journal of Biological Chemistry* 269, 32027–32030. [PubMed: 7528205]

- Stanfel MN, Shamieh LS, Kaerberlein M, Kennedy BK, 2009 The TOR pathway comes of age. *Biochim Biophys Acta* 1790, 1067–1074. [PubMed: 19539012]
- Strong R, Miller RA, Antebi A, Astle CM, Bogue M, Denzel MS, Fernandez E, Flurkey K, Hamilton KL, Lamming DW, Javors MA, de Magalhães JP, Martinez PA, McCord JM, Miller BF, Müller M, Nelson JF, Ndukum J, Rainger GE, Richardson A, Sabatini DM, Salmon AB, Simpkins JW, Steegenga WT, Nadon NL, Harrison DE, 2016 Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an α -glucosidase inhibitor or a Nrf2-inducer. *Aging Cell* 15, 872–884. [PubMed: 27312235]
- Strong R, Miller RA, Astle CM, Baur JA, de Cabo R, Fernandez E, Guo W, Javors M, Kirkland JL, Nelson JF, Sinclair DA, Teter B, Williams D, Zaveri N, Nadon NL, Harrison DE, 2013 Evaluation of resveratrol, green tea extract, curcumin, oxaloacetic acid, and medium-chain triglyceride oil on life span of genetically heterogeneous mice. *J Gerontol A Biol Sci Med Sci* 68, 6–16. [PubMed: 22451473]
- Suchankova G, Nelson LE, Gerhart-Hines Z, Kelly M, Gauthier MS, Saha AK, Ido Y, Puigserver P, Ruderman NB, 2009 Concurrent regulation of AMP-activated protein kinase and SIRT1 in mammalian cells. *Biochemical and biophysical research communications* 378, 836–841. [PubMed: 19071085]
- Suckow B, Suckow M, 2006 Lifespan Extension by the Antioxidant Curcumin in *Drosophila Melanogaster*. *International Journal of Biomedical Science* 2, 402–405. [PubMed: 23675008]
- Suh Y, Atzmon G, Cho MO, Hwang D, Liu B, Leahy DJ, Barzilai N, Cohen P, 2008 Functionally significant insulin-like growth factor I receptor mutations in centenarians. *Proc Natl Acad Sci U S A* 105, 3438–3442. [PubMed: 18316725]
- Sundaram JR, Poore CP, Sulaimi NHB, Pareek T, Cheong WF, Wenk MR, Pant HC, Frautschy SA, Low CM, Kesavapany S, 2017 Curcumin Ameliorates Neuroinflammation, Neurodegeneration, and Memory Deficits in p25 Transgenic Mouse Model that Bears Hallmarks of Alzheimer's Disease. *J Alzheimers Dis* 60, 1429–1442. [PubMed: 29036814]
- Syntichaki P, Troulinaki K, Tavernarakis N, 2007 eIF4E function in somatic cells modulates ageing in *Caenorhabditis elegans*. *Nature* 445, 922–926. [PubMed: 17277769]
- Tain LS, Mortiboys H, Tao RN, Ziviani E, Bandmann O, Whitworth AJ, 2009 Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss. *Nat Neurosci* 12, 1129–1135. [PubMed: 19684592]
- Tan JM, Wong ES, Lim KL, 2009 Protein misfolding and aggregation in Parkinson's disease. *Antioxidants & redox signaling* 11, 2119–2134. [PubMed: 19243238]
- Tapia E, Sanchez-Lozada LG, Garcia-Nino WR, Garcia E, Cerecedo A, Garcia-Arroyo FE, Osorio H, Arellano A, Cristobal-Garcia M, Loreda ML, Molina-Jijon E, Hernandez-Damian J, Negrette-Guzman M, Zazueta C, Huerta-Yepez S, Reyes JL, Madero M, Pedraza-Chaverri J, 2014 Curcumin prevents maleate-induced nephrotoxicity: relation to hemodynamic alterations, oxidative stress, mitochondrial oxygen consumption and activity of respiratory complex I. *Free Radic Res* 48, 1342–1354. [PubMed: 25119790]
- Tardiolo G, Bramanti P, Mazzon E, 2018 Overview on the effects of N-acetylcysteine in neurodegenerative diseases. *Molecules* 23, 3305.
- Taylor JP, Brown RH Jr., Cleveland DW, 2016 Decoding ALS: from genes to mechanism. *Nature* 539, 197–206. [PubMed: 27830784]
- Tchantchou F, Graves M, Rogers E, Ortiz D, Shea TB, 2005 N-acetyl cysteine alleviates oxidative damage to central nervous system of ApoE-deficient mice following folate and vitamin E-deficiency. *Journal of Alzheimer's Disease* 7, 135–138.
- Turner BJ, Baumer D, Parkinson NJ, Scaber J, Ansoorge O, Talbot K, 2008 TDP-43 expression in mouse models of amyotrophic lateral sclerosis and spinal muscular atrophy. *BMC Neurosci* 9, 104. [PubMed: 18957104]
- Turner RS, Thomas RG, Craft S, van Dyck CH, Mintzer J, Reynolds BA, Brewer JB, Rissman RA, Raman R, Aisen PS, 2015 A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. *Neurology* 85, 1383–1391. [PubMed: 26362286]

- UKPDS, 1998 Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. *Lancet* 352, 854–865. [PubMed: 9742977]
- Ungvari Z, Orosz Z, Rivera A, Labinskyy N, Xiangmin Z, Olson S, Podlutzky A, Csiszar A, 2007 Resveratrol increases vascular oxidative stress resistance. *American journal of physiology. Heart and circulatory physiology* 292, H2417–2424. [PubMed: 17220179]
- Valenzano DR, Terzibasi E, Genade T, Cattaneo A, Domenici L, Cellerino A, 2006 Resveratrol Prolongs Lifespan and Retards the Onset of Age-Related Markers in a Short-Lived Vertebrate. *Current Biology* 16, 296–300. [PubMed: 16461283]
- Van Damme P, Robberecht W, Van Den Bosch L, 2017 Modelling amyotrophic lateral sclerosis: progress and possibilities. *Disease Models & Mechanisms* 10, 537. [PubMed: 28468939]
- van der Merwe C, van Dyk HC, Engelbrecht L, van der Westhuizen FH, Kinnear C, Loos B, Bardien S, 2017 Curcumin Rescues a PINK1 Knock Down SH-SY5Y Cellular Model of Parkinson's Disease from Mitochondrial Dysfunction and Cell Death. *Mol Neurobiol* 54, 2752–2762. [PubMed: 27003823]
- Van Skike CE, Jahrling JB, Olson AB, Sayre NL, Hussong SA, Ungvari Z, Lechleiter JD, Galvan V, 2018 Inhibition of mTOR protects the blood-brain barrier in models of Alzheimer's disease and vascular cognitive impairment. *Am J Physiol Heart Circ Physiol* 314, H693–H703. [PubMed: 29351469]
- Vaziri H, Dessain SK, Eaton EN, Imai S-I, Frye RA, Pandita TK, Guarente L, Weinberg RA, 2001 hSIR2/SIRT1 Functions as an NAD-Dependent p53 Deacetylase. *Cell* 107, 149–159. [PubMed: 11672523]
- Vázquez-Manrique RP, Farina F, Cambon K, Dolores Sequedo M, Parker AJ, Millán JM, Weiss A, Déglon N, Neri C, 2016 AMPK activation protects from neuronal dysfunction and vulnerability across nematode, cellular and mouse models of Huntington's disease. *Hum Mol Genet* 25, 1043–1058. [PubMed: 26681807]
- Vingtdeux V, Giliberto L, Zhao H, Chandakkar P, Wu Q, Simon JE, Janle EM, Lobo J, Ferruzzi MG, Davies P, Marambaud P, 2010 AMP-activated protein kinase signaling activation by resveratrol modulates amyloid-beta peptide metabolism. *The Journal of biological chemistry* 285, 9100–9113. [PubMed: 20080969]
- Viswanathan M, Kim SK, Berdichevsky A, Guarente L, 2005 A Role for SIR-2.1 Regulation of ER Stress Response Genes in Determining *C. elegans* Life Span. *Developmental Cell* 9, 605–615. [PubMed: 16256736]
- Vitaglione P, Sforza S, Galaverna G, Ghidini C, Caporaso N, Vescovi PP, Fogliano V, Marchelli R, 2005 Bioavailability of trans-resveratrol from red wine in humans. *Molecular nutrition & food research* 49, 495–504. [PubMed: 15830336]
- Wahlqvist ML, Lee M-S, Hsu C-C, Chuang S-Y, Lee J-T, Tsai H-N, 2012 Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson's disease occurring with Type 2 diabetes in a Taiwanese population cohort. *Parkinsonism Relat Disord* 18, 753–758. [PubMed: 22498320]
- Walle T, Hsieh F, DeLegge MH, Oatis JE Jr., Walle UK, 2004 High absorption but very low bioavailability of oral resveratrol in humans. *Drug metabolism and disposition: the biological fate of chemicals* 32, 1377–1382. [PubMed: 15333514]
- Wang IF, Guo BS, Liu YC, Wu CC, Yang CH, Tsai KJ, Shen CK, 2012 Autophagy activators rescue and alleviate pathogenesis of a mouse model with proteinopathies of the TAR DNA-binding protein 43. *Proc Natl Acad Sci U S A* 109, 15024–15029. [PubMed: 22932872]
- Wang X, Kim J, Lee S, Kim Y, Jung M, Kwon H, Ahn Y, 2014 Effects of curcuminoids identified in rhizomes of *Curcuma longa* on BACE-1 inhibitory and behavioral activity and lifespan of Alzheimer's disease *Drosophila* models. *BMC Complementary and Alternative Medicine* 14, 88. [PubMed: 24597901]
- Wang YL, Ju B, Zhang YZ, Yin HL, Liu YJ, Wang SS, Zeng ZL, Yang XP, Wang HT, Li JF, 2017 Protective Effect of Curcumin Against Oxidative Stress-Induced Injury in Rats with Parkinson's Disease Through the Wnt/ beta-Catenin Signaling Pathway. *Cell Physiol Biochem* 43, 2226–2241. [PubMed: 29069652]

- Wang ZH, Zhang JL, Duan YL, Zhang QS, Li GF, Zheng DL, 2015 MicroRNA-214 participates in the neuroprotective effect of Resveratrol via inhibiting alpha-synuclein expression in MPTP-induced Parkinson's disease mouse. *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie* 74, 252–256. [PubMed: 26349993]
- Wilkinson JE, Burmeister L, Brooks SV, Chan C-C, Friedline S, Harrison DE, Hejtmancik JF, Nadon N, Strong R, Wood LK, Woodward MA, Miller RA, 2012 Rapamycin slows aging in mice. *Aging Cell* 11, 675–682. [PubMed: 22587563]
- Wood JG, Rogina B, Lavu S, Howitz K, Helfand SL, Tatar M, Sinclair D, 2004 Sirtuin activators mimic caloric restriction and delay ageing in metazoans. *Nature* 430, 686–689. [PubMed: 15254550]
- Wright DJ, Renoir T, Smith ZM, Frazier AE, Francis PS, Thorburn DR, McGee SL, Hannan AJ, Gray LJ, 2015 N-Acetylcysteine improves mitochondrial function and ameliorates behavioral deficits in the R6/1 mouse model of Huntington's disease. *Translational Psychiatry* 5, e492–e492. [PubMed: 25562842]
- Wu JW, Boudreau DM, Park Y, Simonds NI, Freedman AN, 2014 Commonly used diabetes and cardiovascular medications and cancer recurrence and cancer-specific mortality: a review of the literature. *Expert Opinion on Drug Safety* 13, 1071–1099. [PubMed: 24999107]
- Wu Y, Li X, Zhu JX, Xie W, Le W, Fan Z, Jankovic J, Pan T, 2011 Resveratrol-activated AMPK/SIRT1/autophagy in cellular models of Parkinson's disease. *Neuro-Signals* 19, 163–174. [PubMed: 21778691]
- Xia D, Sui R, Zhang Z, 2019 Administration of resveratrol improved Parkinson's disease-like phenotype by suppressing apoptosis of neurons via modulating the MALAT1/miR-129/SNCA signaling pathway. *Journal of cellular biochemistry* 120, 4942–4951. [PubMed: 30260025]
- Xu Y, Hou XY, Liu Y, Zong YY, 2009 Different protection of K252a and N-acetyl-L-cysteine against amyloid-beta peptide-induced cortical neuron apoptosis involving inhibition of MLK3-MKK7-JNK3 signal cascades. *J Neurosci Res* 87, 918–927. [PubMed: 18951497]
- Yadav VS, Mishra KP, Singh DP, Mehrotra S, Singh VK, 2005 Immunomodulatory effects of curcumin. *Immunopharmacol Immunotoxicol* 27, 485–497. [PubMed: 16237958]
- Yang F, Lim GP, Begum AN, Ubada OJ, Simmons MR, Ambegaokar SS, Chen PP, Kaye R, Glabe CG, Frautschy SA, Cole GM, 2005 Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. *J Biol Chem* 280, 5892–5901. [PubMed: 15590663]
- Yang W, Hekimi S, 2010 A mitochondrial superoxide signal triggers increased longevity in *Caenorhabditis elegans*. *PLoS biology* 8, e1000556. [PubMed: 21151885]
- Yu WH, Cuervo AM, Kumar A, Peterhoff CM, Schmidt SD, Lee JH, Mohan PS, Mercken M, Farmery MR, Tjernberg LO, Jiang Y, Duff K, Uchiyama Y, Naslund J, Mathews PM, Cataldo AM, Nixon RA, 2005 Macroautophagy--a novel Beta-amyloid peptide-generating pathway activated in Alzheimer's disease. *J Cell Biol* 171, 87–98. [PubMed: 16203860]
- Zafarullah M, Li WQ, Sylvester J, Ahmad M, 2003 Molecular mechanisms of N-acetylcysteine actions. *Cellular and Molecular Life Sciences CMLS* 60, 6–20. [PubMed: 12613655]
- Zbarsky V, Datta KP, Parkar S, Rai DK, Aruoma OI, Dexter DT, 2005 Neuroprotective properties of the natural phenolic antioxidants curcumin and naringenin but not quercetin and fisetin in a 6-OHDA model of Parkinson's disease. *Free Radic Res* 39, 1119–1125. [PubMed: 16298737]
- Zhang C, Browne A, Child D, Tanzi RE, 2010a Curcumin decreases amyloid-beta peptide levels by attenuating the maturation of amyloid-beta precursor protein. *J Biol Chem* 285, 28472–28480. [PubMed: 20622013]
- Zhang CS, Li M, Ma T, Zong Y, Cui J, Feng JW, Wu YQ, Lin SY, Lin SC, 2016 Metformin Activates AMPK through the Lysosomal Pathway. *Cell Metab* 24, 521–522. [PubMed: 27732831]
- Zhang F, Liu J, Shi J-S, 2010b Anti-inflammatory activities of resveratrol in the brain: Role of resveratrol in microglial activation. *European journal of pharmacology* 636, 1–7. [PubMed: 20361959]
- Zhang J, 2006 Resveratrol inhibits insulin responses in a Sirt1-independent pathway. *The Biochemical journal* 397, 519–527. [PubMed: 16626303]

- Zhang J, Lin Y, Dai X, Fang W, Wu X, Chen X, 2019 Metformin treatment improves the spatial memory of aged mice in an APOE genotype-dependent manner. *FASEB J* 33, 7748–7757. [PubMed: 30894020]
- Zhang LF, Yu XL, Ji M, Liu SY, Wu XL, Wang YJ, Liu RT, 2018 Resveratrol alleviates motor and cognitive deficits and neuropathology in the A53T alpha-synuclein mouse model of Parkinson's disease. *Food & function* 9, 6414–6426. [PubMed: 30462117]
- Zhang S, Salemi J, Hou H, Zhu Y, Mori T, Giunta B, Obregon D, Tan J, 2010c Rapamycin promotes beta-amyloid production via ADAM-10 inhibition. *Biochem Biophys Res Commun* 398, 337–341. [PubMed: 20542014]
- Zhang X, Li L, Chen S, Yang D, Wang Y, Zhang X, Wang Z, Le W, 2011 Rapamycin treatment augments motor neuron degeneration in SOD1(G93A) mouse model of amyotrophic lateral sclerosis. *Autophagy* 7, 412–425. [PubMed: 21193837]
- Zhang Y, Bokov A, Gelfond J, Soto V, Ikeno Y, Hubbard G, Diaz V, Sloane L, Maslin K, Treaster S, Rendon S, van Remmen H, Ward W, Javors M, Richardson A, Austad SN, Fischer K, 2014 Rapamycin extends life and health in C57BL/6 mice. *J Gerontol A Biol Sci Med Sci* 69, 119–130. [PubMed: 23682161]
- Zhao HF, Li N, Wang Q, Cheng XJ, Li XM, Liu TT, 2015 Resveratrol decreases the insoluble A β 1–42 level in hippocampus and protects the integrity of the blood–brain barrier in AD rats. *Neuroscience* 310, 641–649. [PubMed: 26454022]
- Zhou C, Huang Y, Przedborski S, 2008 Oxidative stress in Parkinson's disease: a mechanism of pathogenic and therapeutic significance. *Annals of the New York Academy of Sciences* 1147, 93–104. [PubMed: 19076434]
- Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE, 2001 Role of AMP-activated protein kinase in mechanism of metformin action. *J Clin Invest* 108, 1167–1174. [PubMed: 11602624]
- Zhu CW, Grossman H, Neugroschl J, Parker S, Burden A, Luo X, Sano M, 2018 A randomized, double-blind, placebo-controlled trial of resveratrol with glucose and malate (RGM) to slow the progression of Alzheimer's disease: A pilot study. *Alzheimer's & dementia (New York, N. Y.)* 4, 609–616.
- Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, Kachergus J, Hulihan M, Uitti RJ, Calne DB, Stoessl AJ, Pfeiffer RF, Patenge N, Carbajal IC, Vieregge P, Asmus F, Muller-Myhsok B, Dickson DW, Meitinger T, Strom TM, Wszolek ZK, Gasser T, 2004 Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. *Neuron* 44, 601–607. [PubMed: 15541309]
- Zlokovic BV, 2011 Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. *Nat Rev Neurosci* 12, 723–738. [PubMed: 22048062]

Highlights

- Aging is the greatest risk factor for the development of neurodegenerative disease
- Multiple compounds have been shown to extend lifespan in model organisms
- These lifespan-extending compounds have been shown to be neuroprotective in animal models of disease
- Targeting the aging process may be an effective strategy to treat neurodegeneration




Figure 1. Lifespan-extending compounds can be protective in neurodegenerative diseases. Five compounds that have been shown to increase lifespan in model organisms (metformin, resveratrol, rapamycin, N-acetyl cysteine, curcumin) have all been shown to have beneficial effects in four different neurodegenerative diseases (Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis).

Table 1.

Effect of compounds on lifespan in model organisms

| Compound | Mechanisms | <i>C. elegans</i> | <i>Drosophila</i> | Mouse |
|---------------------|---|-------------------------|---------------------------|--|
| Metformin | Activates AMPK Activates mTORC1 | Increase ¹ | No effect ² | Increase ³ No effect ⁴ |
| Resveratrol | Activates SIRT1 Activates AMPK Antioxidant Anti-inflammatory | Increase ⁵⁻⁸ | Increase ^{5, 9} | No effect ¹⁰ Increase ¹¹ (mice on high fat diet) |
| Rapamycin | mTORC1 inhibition | Increase ¹² | Increase ¹³ | Increase ¹⁴⁻¹⁸ |
| N-acetyl-L-cysteine | Antioxidant | Increase ¹⁹ | Increase ²⁰ | Increase ²¹ (possibly through dietary restriction) |
| Curcumin | Antioxidant Anti-inflammatory | Increase ²² | Increase ²³⁻²⁶ | Increase ²⁷ No effect ²⁸ |

¹. Onken B, et al. (2010) *PLoS one* 5(1).

². Slack C, et al. (2012) *PLoS one* 7(10).

³. Martin-Montalvo A, et al. (2013) *Nat Commun* 4.

⁴. Strong R, et al. (2016) *Aging Cell* 15(5).

⁵. Wood JG, et al. (2004) *Nature* 430(7000).

⁶. Viswanathan M, et al. (2005) *Developmental Cell* 9(5).

⁷. Bass TM, et al. (2007) *Mechanisms of ageing and development* 128(10).

⁸. Gruber J, et al. (2007) *Annals of the New York Academy of Sciences* 1100.

⁹. Bauer JH, et al. (2004) *Proceedings of the National Academy of Sciences of the United States of America* 101(35).

¹⁰. Pearson KJ, et al. (2008) *Cell Metab* 8(2).

¹¹. Baur JA, et al. (2006) *Nature* 444(7117).

¹². Robida-Stubbs S, et al. (2012) *Cell metabolism* 15(5).

¹³. Bjedov I, et al. (2010) *Cell Metab* 11(1).

¹⁴. Harrison DE, et al. (2009) *Nature* 460(7253).

¹⁵. Miller RA, et al. (2011) *J Gerontol A Biol Sci Med Sci* 66(2).

¹⁶. Wilkinson JE, et al. (2012) *Aging Cell* 11(4).

¹⁷. Fok WC, et al. (2014) *PLoS One* 9(1).

¹⁸. Zhang Y, et al. (2014) *J Gerontol A Biol Sci Med Sci* 69(2).

¹⁹. Oh S-I, et al. (2015) *Clinics* 70(5).

²⁰. Brack C, et al. (1997) *Cellular and Molecular Life Sciences CMLS* 53(11).

²¹. Flurkey K, et al. (2010) *Journals of Gerontology Series A: Biomedical Sciences and Medical Sciences* 65(12).

22. Liao VH, et al. (2011) *Mech Ageing Dev* 132(10).
23. Suckow B, et al. (2006) *International journal of Biomedical science* 4.
24. Shen LR, et al. (2013) *Age (Dordr)* 35(4).
25. Akinyemi AJ, et al. (2018) *Metab Brain Dis* 33(2).
26. Soh JW, et al. (2013) *Exp Gerontol* 48(2).
27. Kitani K, et al. (2007) *Biogerontology* 8(5).
28. Strong R, et al. (2013) *J Gerontol A Biol Sci Med Sci* 68(1).

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 2.

Effect of compounds on Alzheimer's disease

| Compound | Cell Culture | <i>C. elegans</i> | <i>Drosophila</i> | Mouse | Human |
|-------------|-------------------------------|--------------------------|------------------------------|--|--|
| Metformin | Protective ^{1, 2} | Protective ³ | Protective ⁴ | Protective ⁵⁻¹⁰ Deleterious ¹¹ | Protective ¹²⁻¹⁶ Deleterious ^{17, 18} |
| Resveratrol | Protective ¹⁹⁻²⁴ | Protective ²⁵ | N/A | Protective ²⁶⁻³² | Protective ^{33, 34} No effect ³⁵ |
| Rapamycin | Deleterious ^{36, 37} | N/A | Protective ^{38, 39} | Protective ⁴⁰⁻⁴³ Deleterious ⁴⁴ | N/A |
| NAC | Protective ⁴⁵ | N/A | N/A | Protective ^{46, 47} | Protective ⁴⁸ |
| Curcumin | Protective ^{49, 50} | Protective ⁵¹ | Protective ⁵² | Protective ⁵³⁻⁵⁵ | N/A |

¹.Chen B, et al. (2016) *Biomed Res Int* 2016.

².Li L-X, et al. (2019) *Basic Clin Pharmacol Toxicol* 125(5).

³.Ahmad W, et al. (2017) *Mol Neurobiol* 54(7).

⁴.Niccoli T, et al. (2016) *Curr Biol* 26(17).

⁵.Farr SA, et al. (2019) *J Alzheimers Dis* 68(4).

⁶.Ou Z, et al. (2018) *Brain Behav Immun* 69.

⁷.Nassar SZ, et al. (2018) *Arch Physiol Biochem*.

⁸.Chen J-L, et al. (2019) *Experimental neurology* 311.

⁹.Zhang J, et al. (2019) *FASEB J* 33(6).

¹⁰.Matthes F, et al. (2018) *Cell Death Discov* 4.

¹¹.Barini E, et al. (2016) *Mol Neurodegener* 11.

¹².Shi Q, et al. (2019) *BMJ Open* 9(7).

¹³.Bohlken J, et al. (2018) *J Alzheimers Dis* 66(2).

¹⁴.Orkaby AR, et al. (2017) *Neurology* 89(18).

¹⁵.Cheng C, et al. (2014) *The journals of gerontology. Series A, Biological sciences and medical sciences* 69(10).

¹⁶.Hsu C-C, et al. (2011) *J Alzheimers Dis* 24(3).

¹⁷.Imfeld P, et al. (2012) *J Am Geriatr Soc* 60(5).

¹⁸.Kuan Y-C, et al. (2017) *Prog Neuropsychopharmacol Biol Psychiatry* 79(Pt B).

¹⁹.Marambaud P, et al. (2005) *The Journal of biological chemistry* 280(45).

²⁰.Vingtdeux V, et al. (2010) *The Journal of biological chemistry* 285(12).

²¹.Granzotto A, et al. (2011) *PLoS one* 6(6).

²².Cristòfol R, et al. (2012) *Journal of pineal research* 52(3).

23. Feng X, et al. (2013) *PloS one* 8(3).
24. Wang H, et al. (2018) *Toxicology letters* 282.
25. Regitz C, et al. (2016) *European journal of nutrition* 55(2).
26. Kim D, et al. (2007) *The EMBO journal* 26(13).
27. Karuppagounder SS, et al. (2009) *Neurochemistry international* 54(2).
28. Gong Q-H, et al. (2010) *Journal of Health Science* 56(6).
29. Huang T-C, et al. (2011) *PloS one* 6(12).
30. Porquet D, et al. (2013) *AGE* 35(5).
31. Wang G, et al. (2016) *Oncotarget* 7(14).
32. Capiralla H, et al. (2012) *J Neurochem* 120(3).
33. Turner RS, et al. (2015) *Neurology* 85(16).
34. Moussa C, et al. (2017) *Journal of neuroinflammation* 14(1).
35. Zhu CW, et al. (2018) *Alzheimer's & dementia (New York, N. Y.)* 4.
36. Yu WH, et al. (2005) *J Cell Biol* 171(1).
37. Lafay-Chebassier C, et al. (2006) *J Neurosci Res* 84(6).
38. Berger Z, et al. (2006) *Hum Mol Genet* 15(3).
39. Khurana V, et al. (2006) *Curr Biol* 16(3).
40. Spilman P, et al. (2010) *PLOS ONE* 5(4).
41. Majumder S, et al. (2011) *PLoS One* 6(9).
42. Caccamo A, et al. (2010) *Journal of Biological Chemistry* 285.
43. Van Skike CE, et al. (2018) *Am J Physiol Heart Circ Physiol* 314(4).
44. Zhang S, et al. (2010) *Biochem Biophys Res Commun* 398(3).
45. Tardiolo G, et al. (2018) *Molecules* 23(12).
46. Costa M, et al. (2016) *Chem Biol Interact* 253.
47. Shahidi S, et al. (2017) *Brain Res Bull* 131.
48. Adair JC, et al. (2001) *Neurology* 57(8).
49. Qian W, et al. (2018) *Med Sci Monit* 24.
50. Reddy PH, et al. (2016) *J Investig Med* 64(8).
51. Kim BK, et al. (2019) *Drug Discov Ther* 13(4).
52. Caesar I, et al. (2012) *PLoS One* 7(2).
53. Ahmed T, et al. (2010) *Neuroscience* 169(3).
54. Frautschy S, et al. (2001) *Neurobiology of Aging*
55. Garcia-Alloza M, et al. (2007) *J Neurochem* 102(4).

Table 3.

Effect of compounds on Parkinson's disease

| Compound | Cell Culture | <i>C. elegans</i> | <i>Drosophila</i> | Mouse | Human |
|-------------|------------------------------|--------------------------|---------------------------|--------------------------------------|--|
| Metformin | Protective ¹⁻⁴ | Protective ⁵ | Protective ⁶ | Protective ^{1, 2, 4, 7, 8} | Protective ^{9, 10} Deleterious ¹¹ |
| Resveratrol | Protective ¹²⁻¹⁵ | N/A | Deleterious ¹⁶ | Protective ^{15, 17-23} | N/A |
| Rapamycin | Protective ^{24, 25} | Protective ²⁶ | Protective ²⁷ | Protective ^{24, 25, 28, 29} | N/A |
| NAC | Protective ³⁰ | N/A | N/A | Protective ^{31, 32} | Protective ³⁰ |
| Curcumin | Protective ³³⁻³⁶ | N/A | Protective ³⁷ | Protective ³⁸⁻⁴⁵ | N/A |

¹. Lu M, et al. (2016) *Int J Neuropsychopharmacol* 19(9).

². Bayliss JA, et al. (2016) *PloS one* 11(7).

³. Dulovic M, et al. (2014) *Neurobiology of disease* 63.

⁴. Kang H, et al. (2017) *Oncotarget* 8(30).

⁵. Saewanee N, et al. (2019) *Neuroscience Research*.

⁶. Ng C-H, et al. (2012) *J Neurosci* 32(41).

⁷. Adedeji HA, et al. (2014) *Prog Neuropsychopharmacol Biol Psychiatry* 48.

⁸. Yan Q, et al. (2017) *Mol Pharmacol* 92(6).

⁹. Wahlqvist ML, et al. (2012) *Parkinsonism Relat Disord* 18(6).

¹⁰. Shi Q, et al. (2019) *BMJ Open* 9(7).

¹¹. Kuan Y-C, et al. (2017) *Prog Neuropsychopharmacol Biol Psychiatry* 79(Pt B).

¹². Alvira D, et al. (2007) *Neuroscience* 147(3).

¹³. Wu Y, et al. (2011) *Neuro-Signals* 19(3).

¹⁴. Ferretta A, et al. (2014) *Biochimica et biophysica acta* 1842(7).

¹⁵. Wang ZH, et al. (2015) *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie* 74.

¹⁶. Bagatini PB, et al. (2011) *Invertebrate neuroscience : IN* 11(1).

¹⁷. Blanchet J, et al. (2008) *Progress in neuro-psychopharmacology & biological psychiatry* 32(5).

¹⁸. Jin F, et al. (2008) *European journal of pharmacology* 600(1-3).

¹⁹. Khan MM, et al. (2010) *Brain research* 1328.

²⁰. Gaballah HH, et al. (2016) *Chemico-biological interactions* 251.

²¹. Zhang LF, et al. (2018) *Food & function* 9(12).

²². Liu Q, et al. (2019) *Behavioural brain research* 367.

²³. Xia D, et al. (2019) *Journal of cellular biochemistry* 120(4).

24. Malagelada C, et al. (2010) *J Neurosci* 30(3).
25. Dehay B, et al. (2010) *J Neurosci* 30(37).
26. Tyson T, et al. (2017) *Sci Rep* 7(1).
27. Tain LS, et al. (2009) *Nat Neurosci* 12(9).
28. Masini D, et al. (2018) *Front Neuro* 9.
29. Crews L, et al. (2010) *PLoS One* 5(2).
30. Monti DA, et al. (2016) *PLoS One* 11(6).
31. Rahimmi A, et al. (2015) *Brain Research Bulletin* 113.
32. Clark J, et al. (2010) *PloS one* 5(8).
33. van der Merwe C, et al. (2017) *Mol Neurobiol* 54(4).
34. Jayaraj RL, et al. (2013) *J Mol Neurosci* 51(3).
35. Qualls Z, et al. (2014) *Neurotox Res* 25(1).
36. Sang Q, et al. (2018) *Cell Physiol Biochem* 51(2).
37. Nguyen TT, et al. (2018) *Oxid Med Cell Longev* 2018.
38. Zbarsky V, et al. (2005) *Free Radic Res* 39(10).
39. Du XX, et al. (2012) *Neurosci Bull* 28(3).
40. Rajeswari A, et al. (2008) *Inflammopharmacology* 16(2).
41. Chiu S, et al. (2013) *J Complement Integr Med* 10.
42. Pan J, et al. (2012) *Translational Neurodegeneration* 1.
43. Jayaraj RL, et al. (2014) *Biomed Res Int* 2014.
44. Abbaoui A, et al. (2017) *Neurosci Lett* 660.
45. Sharma N, et al. (2018) *Inflammopharmacology* 26(2).

Table 4.

Effect of compounds on Huntington's disease

| Compound | Cell Culture | <i>C. elegans</i> | <i>Drosophila</i> | Mouse | Human |
|-------------|-----------------------------|---------------------------|----------------------------|---|-------------------------|
| Metformin | Protective ¹ | Protective ^{2,3} | N/A | Protective ^{2,4,5} | Protective ⁶ |
| Resveratrol | Protective ^{7,8} | Protective ⁷ | Protective ^{9,10} | Protective ^{8,11,12} | N/A |
| Rapamycin | Protective ^{13,14} | N/A | Protective ¹⁵ | Protective ¹⁵ No effect ¹⁶ | N/A |
| NAC | N/A | N/A | N/A | Protective ^{17,18} | N/A |
| Curcumin | N/A | N/A | Protective ¹⁹ | Protective ²⁰ | N/A |

¹Jin J, et al. (2016) *Neuromolecular Med* 18(4).

²Sanchis A, et al. (2019) *Exp Mol Med* 51(6).

³Vázquez-Manrique RP, et al. (2016) *Hum Mol Genet* 25(6).

⁴Arnoux I, et al. (2018) *Elife* 7.

⁵Ma TC, et al. (2007) *Neurosci Lett* 411(2).

⁶Hervás D, et al. (2017) *PloS one* 12(6).

⁷Parker JA, et al. (2005) *Nature genetics* 37(4).

⁸Naia L, et al. (2017) *Molecular neurobiology* 54(7).

⁹Pallos J, et al. (2008) *Human molecular genetics* 17(23).

¹⁰Maier P, et al. (2011) *Human molecular genetics* 20(2).

¹¹Ho DJ, et al. (2010) *Experimental neurology* 225(1).

¹²Gerhardt E, et al. (2011) *PloS one* 6(12).

¹³Ravikumar BD, R.; Rubinsztein, C. (2002) *Hum Mol Genet* 11.

¹⁴King MA, et al. (2008) *Mol Pharmacol* 73(4).

¹⁵Ravikumar B, et al. (2004) *Nat Genet* 36(6).

¹⁶Fox JH, et al. (2010) *Mol Neurodegener* 5.

¹⁷Sandhir R, et al. (2012) *Neurodegenerative Diseases* 9(3).

¹⁸Wright DJ, et al. (2015) *Translational Psychiatry* 5(1).

¹⁹Chongtham A, et al. (2016) *Sci Rep* 6.

²⁰Hickey MA, et al. (2012) *Mol Neurodegener* 7.

Table 5.

Effect of Compounds on Amyotrophic lateral sclerosis

| ALS | Cell Culture | <i>C. elegans</i> | <i>Drosophila</i> | Mouse | Human |
|-------------|------------------------------|-------------------|-------------------------|---|------------------------------|
| Metformin | N/A | N/A | N/A | Deleterious ¹ | No effect ² |
| Resveratrol | Protective ³ | N/A | N/A | Protective ⁴ | N/A |
| Rapamycin | Protective ⁵ | N/A | Protective ⁶ | Protective ⁷ No effect ⁸ Deleterious ⁹ | In Progress ¹⁰ |
| NAC | Protective ¹¹ | N/A | N/A | Protective ¹² | Deleterious ¹³ |
| Curcumin | Protective ^{14, 15} | N/A | N/A | N/A | Protective ^{16, 17} |

^{1.} Kaneb HM, et al. (2011) *PLoS one* 6(9).

^{2.} Bond L, et al. (2020) *Behavioral Sciences* 10(1).

^{3.} Kim D, et al. (2007) *The EMBO journal* 26(13).

^{4.} Mancuso R, et al. (2014) *Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics* 11(2).

^{5.} Caccamo A, et al. (2009) *J Biol Chem* 284(40).

^{6.} Cheng CW, et al. (2015) *J Neurogenet* 29(2–3).

^{7.} Wang IF, et al. (2012) *Proc Natl Acad Sci U S A* 109(37).

^{8.} Staats KAH, S.; Schonefeldt, S.; Bento-Abreu, A.; Dooley, J.; Van Damme, P.; Liston, A.; Robberecht, W.; Van Den Bosch, L. (2013) *Mol Neurodegener* 8.

^{9.} Zhang X, et al. (2011) *Autophagy* 7(4).

^{10.} Mandrioli J, et al. (2018) *Medicine (Baltimore)* 97(24).

^{11.} Beretta S, et al. (2003) *Neurobiology of disease* 13(3).

^{12.} Andreassen OA, et al. (2000) *Neuroreport* 11(11).

^{13.} Deepmala, et al. (2015) *Neuroscience & Biobehavioral Reviews* 55.

^{14.} Lu J, et al. (2012) *Brain Res Bull* 89(5–6).

^{15.} Dong H, et al. (2014) *Neuroscience* 272.

^{16.} Ahmadi M, et al. (2018) *Neurotherapeutics* 15(2).

^{17.} Chico L, et al. (2018) *CNS Neurol Disord Drug Targets* 17(10).